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Design and in vitro Characterization of Lipids with a pH-sensitive Conformational Switch and
Their Liposomes for Anticancer Drug Delivery

Abstract

By Shen Zhao
University of the Pacific
2018

The traditional anticancer drugs are distributed in vivo through systemic blood circulation
with a very small portion reaching the tumor site. Targeted drug delivery systems are developed
in efforts to concentrate the drug molecules in the tissue of interest while reducing the drug
distribution to healthy tissues to reduce the side effects. Liposomes are colloidal systems
composed of amphiphilic molecules that assemble into vesicle structures in aqueous media.
They are common carriers for targeted drug delivery with the advantages of low toxicity, low
immunogenicity and the ability of encapsulating both lipophilic and hydrophilic drugs.
Prior research indicated the advantages of triggered release in drug delivery systems. As
a specific example, a series of trans-2-aminocyclohexanol based lipids (flipids) have been
reported to illustrate a promising strategy to render pH-triggered drug delivery systems: pHtriggered conformational switch. Based on the foregoing, we hypothesize that incorporation of
lipids with a pH-sensitive conformational switch and a long-saturated lipid tail can improve the
anticancer activities of stealth liposomes. In this study, six new flipids with C-16 saturated
hydrocarbon tails were designed. Such lipids were synthesized with high yields by introducing a
catalyst (Copper (II) tetrafluoroborate) at a key step of the synthetic scheme.
pH-sensitive liposomes (fliposomes) composed of flipids were prepared and loaded with
the anticancer drug doxorubicin with high encapsulation efficiency. The physicochemical
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properties of doxorubicin-loaded fliposomes were characterized and their pH-dependent leakage
were investigated. The results showed that among all groups fliposomes containing the C-16
trans-2-morpholylcyclohexanol-based flipid (Mor-C16) exhibited the largest increase of release
as the pH dropped form pH 7.4 to 6.0, indicating its good potential of serving as a component in
pH-triggered drug delivery systems.
Three-dimensional multicellular spheroids (3D MCS) are self-assembled microscale
tissue analogs in vitro. They better mimic the native and complex tumor microenvironment than
the conventional two-dimensional cell culture systems. In this dissertation study, 3D MCS of six
different human cancer cells were successfully cultured and their growing conditions were
optimized to obtain 3D MCS of tight structure and reproducible size. The constructed 3D MCS
carried heterogeneously distributed live and apoptotic cells as well as acidic inside pH based on
confocal microscopic imaging studies.
The penetration of doxorubicin-loaded Mor-C16 fliposomes into 3D MCS was imaged by
confocal microscopy in comparison to doxorubicin-loaded non pH-sensitive liposomes and free
doxorubicin. The anticancer activities of doxorubicin-loaded Mor-C16 fliposomes against 3D
MCS of three different cell lines was also evaluated by cell viability. Both the fliposome and the
non pH-sensitive liposome formulations more efficiently penetrated into two of the three types of
3D MCS compared to free doxorubicin after 4h drug exposure. However, doxorubicin-loaded
Mor-C16 fliposome imposed higher cytotoxicity to all three types of 3D MCS compared to
doxorubicin-loaded non pH-sensitive liposome over 72 h drug exposure. Taken together, we
propose that fliposomes achieved superior activity against 3D MCS by efficient penetration into
3D MCS, followed by enhanced release of the anticancer drug doxorubicin.
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Introduction

1.1 Cancer and Solid Tumor
1.1.1 Cancer. Cancer is a collection of related diseases that involve non-stopping
abnormal cell growth with the ability of spreading into surrounding tissues[1]. The term cancer
is derived from the Latin word of crab, meaning “ grab on and don’t let go”[2]. There are over
100 types of cancers affecting humans, which jointly represent the second cause of death in the
United States[3]. The most common cancers worldwide, as reported by World Health
Organization (WHO) in 2018 are listed in Table 1.1.

Table 1.1. Most Common Cancers in 2018[4]
Cancer Types
Lung
Breast
Colorectal
Prostate
Skin (non-melanoma)
Stomach

Cases (million)
2.09
2.09
1.80
1.28
1.04
1.03

Cancer is a genetic disease and arises from the transformation of normal cells into cancer
cells due to the changes of genes that control the cells growth and division. The majority of
cancers are attributed to the genetic mutations from environmental factors while others are due to
inherited genetics[5]. The common environmental factors include:
•

Physical factors: ionizing radiation, ultraviolet
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•

Diet and exercise factors: specific foods, obesity, lack of physical activity

•

Chemical factors: tobacco, aflatoxin, arsenic

•

Biological factors: Helicobacter pylori, hepatitis B, hepatitis C, human papillomavirus,
Epstein-Barr virus and HIV[6].
1.1.2 Solid tumor. A tumor, also known as neoplasm, is an abnormal growth of cells

that form a mass[7]. When the growth occurs in solid tissues such as an organ, muscle or bone,
it is called a solid tumor. Blood cancer do not usually take the form of a solid tumor. There are
two types of solid tumors: benign (noncancerous) and malignant (cancerous). Benign tumors
usually grow slowly and do not invade adjacent tissues. Most of them respond well to
treatments. Malignant tumors are cancerous. They can invade nearby tissues and organs and
may spread to other parts of the body[8]. Based on the types of cells forming the solid tumor,
they can be divided into four categories[9]:
•

Carcinoma: formed from epithelial cells, such as prostate, stomach, lung, pancreas, liver

•

Sarcoma: formed in connective tissues, such as cartilage, fat, bones and nerves

•

Germ cell tumor: sperm and egg cells

•

Blastoma: formed from embryonic tissue
The physiological characteristics of solid tumor (Figure. 1.1) are so different from

normal tissue in that neovasculature is developed in the tumor microenvironment to ensure an
adequate supply of nutrients and oxygen[10]. The newly formed vessels within different parts of
the tumor create an imbalance of pro- and anti-angiogenic signaling, leading to the formation of
abnormal vascular network with dilated, tortuous and saccular channels[11, 12]. Unlike the
ordered microvasculature of normal tissue, tumor microvasculature shows disorganized, enlarged
vessels and unidentifiable arterioles, capillaries and venules[13, 14].
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Figure 1.1. Physiological Characteristics of Tumor Tissue and Vasculatures[15]

Tumor blood vessels show structural abnormalities in that the endothelial surface is
fenestrated with gaps and that the endothelial cells are surrounded by discontinuous
membranes[16, 17]. Furthermore, the lack of lymphatic vessels causes the low clearance of the
interstitial fluid inside the solid tumor. Most nano-sized drug delivery systems with long
circulation times can accumulate within solid tumors by leaking through the abnormal tumor
vasculature and then by retaining inside the tumor due to the reduced lymphatic drainage. This
is the mechanism of the well-known enhanced permeability and retention (EPR) effect[18].
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The cell proliferation inside the solid tumor is heterogeneous because of the imbalanced
blood supply, resulting a higher cellular density near blood vessel[19]. A necrosis zone is
formed in the core of solid tumor due to the lack of nutrients. Multi-gradients of oxygen, carbon
dioxide and pH have been detected inside the solid tumor due to its abnormal
microenvironment[20].
1.1.3 Cancer therapy. There are many types of cancer therapy for different types and
stages of cancer. Traditional anticancer treatments include surgery, radiotherapy and
chemotherapy. Most of the time, a combination of two or more treatments are applied depending
on the condition of the patient[6]. Current common cancer therapies are summarized in Table 2
together with their challenges.

Table 1.2. Types of Cancer Therapy and their Challenges[21]
Types of Cancer Therapy
Surgery

Methodology
Remove cancer tissues
using scalpels, laser,
hyperthermia or
photodynamic therapy

Radiation

Use high doses of radiation
to kill cancer cells or
improve symptoms
Use one or more cytotoxic
drugs to kill cancer cells

Chemotherapy

Immunotherapy

Stimulate or help the
immune system to fight
cancer

Targeted therapy

It is a form of
chemotherapy that targets

Challenges
Works only for solid
tumors that are contained
in one area; pain after
surgery and risk of
infection
Side effects: affect nearby
healthy tissue; cause
fatigue on patient
Side effects: damage to
healthy cells; cause fatigue
on patient
Side effects: skin reactions
at needle site; flu-like
symptoms; heart
palpitations; diarrhea and
risk of infection
Drug resistance; difficulty
in developing drugs for
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specific molecular of
cancer cells
Slows or stops the growth
of cancers (prostate for
male and breast cancer for
female) that need
hormones to grow

Hormone therapy

Precision medicine

It is also called
personalized medicine that
is tailored to the genetic
changes in each patient’s
cancer.

some targets; side effect:
diarrhea and liver problems
Side effects for men: hot
flashes, weakened bones,
diarrhea, nausea and
fatigue
Side effects for women:
hot flashes, nausea, mood
changes and fatigue
Not yet apply to everyone;
treatment using precision
medicine can be expensive

1.2 Anticancer Drugs
The first chemotherapy drug to treat cancer was developed in the early 20th century when
mustard gas was discovered to be a potent suppressor of hematopoiesis[22]. Since then many
other drugs have been developed for the treatment of a variety of cancers with different
stages[23].
1.2.1 Classification of anticancer drugs. Generally, anticancer drugs can be grouped
by their mechanism of actions. Major classes of anticancer drugs include: cytotoxic drugs,
targeted drugs and hormonal drugs (Table 1.3). Understanding of the classification of anticancer
drugs can be useful for a comprehensive view of the available drugs in each class and for the
design of combination treatments[24].

Table 1.3. Classification of Anticancer Drugs[25]
Class
Cytotoxic

•

Type
Alkylating agents

•

Example of drugs
Cisplatin, Carboplatin
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•
•
•

Targeted

•
•
•
•
•
•
•

Hormonal

•
•
•
•
•
•
•

Antimetabolites
Microtubule
damaging agents
Topoisomerase
inhibitor
Antibiotics
Miscellaneous
Tyrosine protein
kinase inhibitor
EGF receptor
inhibitor
Angiogenesis
inhibitor
Proteasome inhibitor
Unarmed
monoclonal antibody
Glucocorticoids
Estrogens
Aromatase inhibitors
Antiandrogen
5-α reductase
inhibitor
GnRH analogues
Progestins

•
•
•
•
•

Methotrexate, Gemcitabine
Vincristine, Vinblastine
Etoposide, Topotecan
Doxorubicin, Bleomycin
Tretinoin, Hydroxyurea

•
•
•
•
•

Imatinib, Nilotinib
Gefitinib, Erlotinib
Bevacizumab
Bortezomib
Rituximab, Trastuzumab

•
•
•
•
•
•
•

Prednisolone
Fosfestrol, ethinylestradiol
Letrozole, Anastrozole
Flutamide
Finasteride
Nafarelin, Triotorelin
Hydroxyprogesterone
acetate

1.2.2 Doxorubicin. Doxorubicin (DOX or DXR) (Figure 1.2), is a member of the
natural products called anthracyclines, which is produced by the soil fungus Streptomyces[26].
DOX is an effective chemotherapeutic belonging to the antibiotic category of cytotoxicity
anticancer drugs[27]. DOX is used to treat a wide range of cancers including breast cancer,
bladder cancer, Kaposi’s sarcoma, lymphoma and acute lymphocytic leukemia[28, 29]. It is
given by an intravenous injection and often used in a combination with other chemotherapy
drugs[30].
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OH

O
OH
OH

H
O

O

OH

O

O

OH
NH2

C27H29 NO11
Exact Mass: 543.17
Mol. Wt.: 543.52
m/e: 543.17 (100.0%), 544.18 (30.9%), 545.18 (6.8%), 546.18 (1.1%)
C, 59.66; H, 5.38; N, 2.58; O, 32.38

Figure 1.2. Chemical Structure of Doxorubicin

The anticancer activity of DOX comes from its interaction with DNA by intercalation
and from inhibition of macromolecular biosynthesis[31, 32]. It is reported that DOX inhibits the
resealing of DNA double helix by the topoisomerase II (TOP II) complex, an enzyme
responsible for relaxing supercoils in DNA during transcription[31]. DOX was also shown to
evict histones to induce cell death that is independent of TOP II[33]. It is highly likely that the
anti-cancer effects of DOX results from a variety of mechanisms of inhibiting DNA
synthesis[34, 35].
DOX was first approved for medical use by FDA in 1974[30]. It is one of the most
effective and essential medicines for cancer therapy according to the World Health
Organizations’ report in 2015[36]. While the majority of anticancer drugs are only effective
towards tumor cells in their exponential phase, DOX can arrest the cell cycle at all stages.
However, the clinical use of DOX is restricted by several side effects including vomiting, bone
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marrow suppression, alopecia, mucositis and especially dose-dependent cardiotoxicity[37, 38].
The most dangerous side effect of DOX is dilated cardiomyopathy with no effective
treatment[39]. The liposome-encapsulated DOX carries less cardiotoxic than free DOX, leading
to the development and approval of the first nano-drug “Doxil”.
DOX is a fluorescent molecule that is typically excited at 480 nm and detected of its
emission between 560 - 590 nm. DOX’s broad spectrum of anticancer activity and fluorescence
makes it an attractive model drug in the development of anticancer drug delivery systems.
1.3 Approaches of Targeted Drug Delivery
Traditional anticancer drugs are distributed in the body through systemic blood
circulation. Only a very small portion of drugs reaches the tumor site. Thus, targeted drug
delivery systems are developed in efforts to concentrate the drug molecules in the tissue of
interest while reducing the drug distribution to healthy tissues to reduce the side effects. Another
advantage of targeted drug delivery would be prolonged drug exposure to tumor, which allow
less frequent dosages. Effective targeted drug delivery systems require 1) efficient drug loading
into carriers, 2) sufficient residence in the blood circulation, 3) enhanced retention in the target
side, and 4) efficient drug release within a period for effective function of the drug[40].
Generally, there are two kinds of drug targeting approaches, passive targeting and active
targeting.
1.3.1 Passive targeting. Passive targeting is the monitoring of the physicochemical
properties of drug delivery systems to influence their distribution in vivo. One important
application of passive targeting is the enhanced permeation and retention (EPR) effect of solid
tumors. As we discussed above, most nano drug delivery systems (10 – 400 nm) with long
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circulation time accumulate more in solid tumors than in normal tissues by permeating
preferentially into tumor tissue through its leaky vasculature and retaining inside due to the lack
of effective lymphatic drainage[18]. The long circulation time of the nanocarriers can be
achieved by coating polyethylene glycol (PEG) to the surface of the delivery systems to
minimize the adsorption of serum proteins that trigger immune responses that promote clearance.
With the PEG coating water molecules can hydrogen bond with the oxygen molecules on PEG to
form a film of hydration around the nanocarriers, thus hinder their detection and clearance by the
mononuclear phagocyte system (MPS)[41]. It was found that the increased systemic circulation
time is dependent upon the molecular weight of the PEG. Generally, higher average molecular
weight of PEG leads to longer circulation time, except that the liver clearance is found to be
enhanced when the average molecular weight of PEG reaches above 50,000[42]. Nanocarriers
with a size between 10 – 100 nm have been found to have a longer systemic circulation time[43].
There are several challenges of passive targeting for anticancer drug delivery. First, the
drug delivery systems must come in close proximity to the tumor site for the EPR effect to take
place. Second, there is a severe lack of clinical data on the EPR effect. The tumor growth rate in
animal models is not comparable to that in human. EPR effect has been found to differ from
tumor to tumor xenografts[44]. Models being used to study EPR in laboratories are not
sufficiently accurate in representing EPR effect in patients. Third, although PEGylated drug
delivery systems have increased systemic circulation times, the actual percentage of PEGylated
nanocarriers accumulating at the tumor site is still very limited. For example, it is shown in an
animal study that only 5% of the administered PEGylated niosomes remained in the systemic
circulation after 12 h and about 80% of the initial dose was eliminated in less than a few
hours[45].
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1.3.2 Active targeting. Active targeting enhances the drug accumulation at the target
site by two strategies: ligand-receptor mediated active targeting and locally activated drug
delivery. The former is achieved by incorporating ligands on the drug carriers’ surface to
selectively bind over-expressed receptors on target cells[46]. The latter is to trigger the drug
release from the carriers either by a signal specific at the site or by external stimulus, such as
light, temperature, magnetic field and ultrasound[47].
Tumor cells overexpress many specific biomarkers on their surface, making it possible to
design ligands for specific binding[48]. Conjugation of tumor-specific ligands to nanocarriers is
a common approach to achieve active targeting that further improves a nano drug delivery
system already with proper physicochemical properties for passive targeting[49]. Following
binding of the ligand with its receptor, the actively targeted nanocarriers can be internalized by
tumor cells through receptor-mediated endocytosis[48]. Several ligands against various tumor
biomarkers have been extensively studied. Some of the most commonly used targeting ligands
that have been conjugated to nanoparticles are listed in Table 1.4, together with their advantages
and challenges.

Table 1.4. Advantages and challenges of commonly used targeting ligands in nanoparticle
conjugations[50]
Ligands conjugated NPs
Transferrin conjugated NPs

•

•

Advantages
Overexpression of
Transferrin receptor
on metastatic and
drug resistant
tumors
Easily conjugated
to a variety of
materials

•
•

Challenges
Nonspecific
distribution and
targeting
A risk of overdose
of iron transport
into brain caused by
an exogenouslysupplied transferrin
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•
•

Cell-penetrating peptides
(CPPs) conjugated NPs

•

•

•

Low-Density Lipoproteins
conjugated NPs

•
•
•
•

•

Integrin modified NPs

•

•

High intracellular
uptake
Prolonged
circulation time and
significantly
increased tumor
accumulation
Be able to cross cell
membrane
independent of
energy
Efficiently
internalize the
associated
biomolecules with
no decreased
biocompatibility
Be able to protect
the bioactive
conjugates from
degradation and
increase the serum
half-life of cargoes
Low cytotoxicity
Natural carrier with
high
biocompatibility
Non-immunogenic
Be able to
encapsulate both
hydrophobic and
amphiphilic drugs
LDL receptor is
highly expressed in
most tumor cells
Some integrins are
highly overexpressed on many
cancer cells
Integrin signaling
control diverse
functions in tumor
cells

•
•

•
•

•

The transmembrane
mechanism is
unclear
The biological
activity of
conjugates may
change in some
cases

Existence of LDL
receptors on normal
cells
Concern of
introduction of
pathogens

Existence of
integrins on normal
cells
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•

Carbohydrates modified
NPs

•
•

Folate modified NPs

•

•
•

Highly accessible
cell surface
receptors
Effective oral
delivery system
Improved
bioavailability
Folate receptor is
overexpressed on
the majority of
cancer cells
Folate is small and
stable
Inexpensive and
nonimmunogenic

•

Some degree of
toxicity

•

Uptake of folate
can sometimes
promote cancer cell
proliferation and
migration

There are a number of challenges in ligand-receptor mediated active targeting. First, the
binding can only occur when the two components are close enough (< 0.5 nm). Current drug
delivery systems do not have the ability to guide themselves to a target beyond the scope[49].
Second, some studies showed that the presence of targeting ligand did not always result in
enhanced accumulation of the drug inside the target site[51, 52]. Third, the expression of a
specific receptor may not be homogenously distributed in a tumor and is subject to change on the
surface over time[53]. Finally, the expression of the receptor in cultured cancer cells in vitro
may not represent the properties in a patient’s tumor.
The locally activated drug delivery system can respond to specific stimuli to trigger the
release of the entrapped drug, leading to an increased accumulation inside the tumor. For
example, activate targeting systems were designed to release the cargo in response to hypoxia
inside the tumor site[54]. Another specific active targeting system was developed to trigger the
payload release based on the lowered pH inside the tumor[55].
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1.3.3 Targeted drug delivery systems. Targeted drug delivery systems have been
developed to treat many diseases, such as cardiovascular diseases and diabetes, but the most
important application of them is to treat cancerous tumors. It has been reported that the pore cutoff size of several tumor models is within the range of 380 and 780 nm[16, 56]. In order to take
the advantage of EPR effect, nano-sized drug delivery systems are extensively studied. Many
terms have been used to describe these nano drug delivery systems including: nanocarrier,
nanovehicle, nanosystem, etc. An ideal nanocarrier must be biocompatible, non-toxic and nonimmunogenic[57]. Most commonly used targeted drug delivery nanocarriers can be classified
into four categories: organic nanocarriers, inorganic nanocarriers, organic/inorganic hybrid
nanocarriers and virus-based nanoparticles[58].
1.3.3.1 Organic nanocarriers. There are many types of organic nanocarriers based on
their compositions and structures. The most commonly used organic nanocarriers include solid
lipid nanoparticles, liposomes, dendrimers (Figure 1.3), polymeric nanoparticles and polymeric
micelles (Table 1.5).
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Figure 1.3. Structure of Dendrimers[58]

Table 1.5. Commonly used Organic Nanocarriers[58]
Organic nanocarriers
Solid lipid nanoparticles

•
•

•
Liposomes

•
•

•
Dendrimers

•

Feature
Size range of 50 –
1,000 nm
Highly lipophilic
lipid matrix for
lipophilic drug
encapsulation
Economical largescale production
Spheroid shape
with aqueous core
and bilayer shell
Capable of
encapsulating both
lipophilic and
hydrophilic drugs
Biodegradable and
biocompatible
Frequently
branched
macromolecules

Preparation method
• Dispersing melted
solid lipid in water
with stabilizer of
emulsifiers by high
pressure
homogenization
and
microemulsification
• Lipid film
hydration
• Ethanol injection

•

Stepwise synthesis
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•
•
•
Polymeric nanoparticles

•
•
•
•
•

Polymeric micelles

•
•
•

•

Distinctive
molecular weight
Average size range
of 1.5 – 14.5 nm
Extraordinarily
controlled shape
Solid colloidal
particles of 10 –
1,000 nm in size
Biodegradable
polymers
High encapsulation
capacity
Good stability on
storage and in vivo
Prolonged
circulation time.
Self-assembled
copolymers of dior tri-block
Small size of 10 –
100 nm
Capable of
encapsulating both
lipophilic and
hydrophilic drugs
Formation above
critical micelle
concentration

•
•

•
•
•
•
•

Dispersion of
preformed
polymers
Direct
polymerization of
monomers

Dialysis
Oil-in-water
emulsion
Solvent evaporation
Co-solvent
evaporation
Freeze-drying
method

1.3.3.2 Inorganic nanocarriers. Certain inorganic materials can be used to make
nanocarriers for drug delivery due to their distinctive physicochemical and biological
characteristics. Carbon nanotubes and mesoporous silica nanoparticles are two examples with
many applications in delivery anticancer drugs, such as paclitaxel[59, 60], doxorubicin[61, 62]
and methotrexate[63, 64].
•

Carbon nanotubes (CNTs): CNTs are tube-like structures of carbon atoms that are formed
by rolling up graphene sheets[65]. Single-walled or multi-walled carbon nanotubes

35
(Figure 1.4) can be formed with an outer diameter of 0.4 – 2 nm and 2 – 100 nm,
respectively[66]. CNTs can be produced using a variety of techniques such as discharge,
laser ablation and thermal chemical vapor deposition[67]. Some of the unique features of
CNTs include nanoneedle shape, high mechanical strength, high electrical and thermal
conductivities. The major limitations of CNTs are their poor water solubility and
toxicity[66].

Figure 1.4. Graphical representation of single-walled CNTs (A) and multi-walled CNTs (B)[58]

•

Mesoporous silica nanoparticles (MSNs): MSNs are honeycomb-like particles (Figure
1.5) with pores of 2 to 50 nm in size[68]. Both hydrophilic and lipophilic drugs can be
loaded into these pores, which make them promising inorganic nanocarriers.
Furthermore, MSNs possess many other advantages including large specific surface area,
good biocompatibility and convenience for mass production[69]. In addition, their
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surface can be easily modified with active targeting ligands to enhance therapeutic
efficacy and to reduce side effects[70].

Figure 1.5. Schematics of MSNs[58]

1.3.3.3 Organic/inorganic hybrid nanocarriers. Organic/inorganic hybrid nanocarriers
are designed to take advantage of both types of nanocarriers and to overcome their limitations.
For example, inorganic nanocarriers of mesoporous silica nanoparticles (MSNs) were coated
with polyethyleneimine (PEI) to form new hybrid nanocarriers that showed enhanced cellular
uptake[71]. In another study, a MSNs/lipid bilayer hybrid system was developed to encapsulate
zoledronic acid for an improved drug retention in a breast cancer model[72]. Han et al, also
reported an increased DOX uptake using a lipid-capped MSNs hybrid system compared with
control groups[73].
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1.3.3.4 Virus-based nanoparticles. Most virus capsids are about 20 – 500 nm in
diameter. They are considered as naturally formed protein cages with uniform nanostructures
and well-defined geometry[74, 75]. Recently, studies of virus-based nanocarriers have been
widely explored for drug delivery, gene therapy, vaccination and targeting[76]. Virus-based
nanoparticles (VNPs) or virus-like particles (VLPs) from different sources have been
investigated because of their attractive features including biocompatibility, morphological
uniformity and high stability[77]. Drugs can either be physically encapsulated in VNPs or
chemically linked to the surface[78]. As a targeted drug delivery nanocarrier, VNPs can be
functionalized for active targeting by either genetic modification or by chemical bioconjugation.
Many studies have suggested that VNPs could be very promising nanocarriers for tumor
targeting[79, 80].
1.4 Liposomes
Liposomes (Scheme 1.1) are colloidal systems composed of amphiphilic molecules, most
often phospholipids, that assemble in aqueous media into spherical structures with one or several
concentric membranes[81]. They have spheroid shape structures with the size ranging from 20
to 10,000 nm. They are the most commonly used carriers for targeted drug delivery with the
advantages of low toxicity, low immunogenicity and biocompatibility[82]. Liposomes can
encapsulate both lipophilic drugs in the lipid bilayer and hydrophilic drugs in the aqueous core.
The major types of liposomes are multilamellar vesicle (MLV), small unilamellar vesicle (SUV)
and large unilamellar vesicle (LUV).
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Scheme 1.1. A Liposome Formed by Amphiphilic Molecules in Aqueous Phase[83]

1.4.1 Conventional liposomes. Conventional liposomes are made up of phospholipids.
Upon intravenous administration, they are rapidly captured by the mononuclear phagocyte
system (MPS) and eliminated from the blood circulation, leading to a very short half-life[84].
This feature of conventional liposome was exploited for efficient delivery of antiparasitic and
antimicrobial drugs to the MPS to treat infections[85, 86]. However, their use is limited when
the target site is beyond MPS. Furthermore, it was reported conventional liposomes could
interact with high and low density lipoproteins in the plasma resulting in rapid release of the
encapsulated drug[87]. It was also found that the enhanced MPS uptake of conventional
liposomes by the liver is size-dependent. Larger liposomes are eliminated by the MPS much
faster than smaller ones[88].
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1.4.2 Stealth liposomes. A stealth liposome (Scheme 1.2), also called a PEGylated
liposome, is a liposome with a poly ethylene glycol (PEG) coating on the outer membrane. PEG
is the most widely used polymeric steric stabilizer that is biocompatible, low toxic and very low
immunogenic. PEG can be incorporated on the liposomal surface in several ways such as 1)
physical adsorption onto the surface of the liposome, 2) covalent attachment onto the surface of
liposome, 3) incorporation of a PEG-lipid conjugate during liposome preparation. The presence
of PEG on the liposome surface significantly reduces the MPS uptake, thus prolongs the half-life
in the blood circulation[89]. In addition, a reduced interaction of stealth liposomes with plasma
proteins also increases the blood circulation time[90]. Furthermore, it was reported that PEG
could stabilize liposome preparations by providing a strong inter-bilayer repulsion that counters
the attractive Van der Waals forces that facilitates liposome aggregation[91].
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Scheme 1.2. A Scheme of PEGylated (Stealth) Liposome

Stealth liposomes are important in cancer therapy. As an example of stealth liposomes,
DOXIL was the first FDA approved PEGylated liposomal formulation containing Doxorubicin.
Stealth liposomes can be further modified by a variety of targeting ligands for active targeting.
Moreover, it is reported that stealth liposomes with a cell-penetrating peptide can be used for
intracellular targeting[87].
1.4.3 Triggered release from liposomes. In order to increase the efficacy of the
anticancer drug payload of liposomes after their accumulation at the target side, many liposome
formulations have been developed to elevate the release of the payload drug in response to
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specific stimuli at the target site (aka triggered release). Common strategies to achieve triggered
release are discussed hereafter.
1.4.3.1 pH-sensitive liposomes. pH-sensitive liposomes (pHSLs) are designed to elevate
the release of the encapsulated drug in response to the pH decrease from blood (pH 7.4) to tumor
interstitium (pH 5.7 – 7.8) or to endosomes/lysosomes (pH 4.5 – 5.5)[92, 93]. Mechanistically,
pH-sensitive liposomes are rapidly destabilized under acidic conditions. pH-sensitivity has been
shown as the most biocompatible strategy for triggered release into cytoplasm[94]. The pHsensitive liposomes have been designed to deliver a variety of agents intracellularly and
intercellularly, such as anticancer drugs, DNA, antisense oligonucleotides, proteins, peptides,
and contrasting agents[95]. More details about pH-sensitive liposomes are discussed in Section
2.1.
1.4.3.2 Thermo-sensitive liposomes. Thermo-sensitive liposomes (TSLs) are designed to
release cargo in response to local hyperthermia[94]. It has the advantage that it is not dependent
on the EPR effect due to its rapid release of the drug in the microvessels of the tumor during
hyperthermia treatment[96]. TLs must be stable at 37°C and yet be able to release the drug in a
slightly higher temperature range of 39-42°C[97]. There are many studies on TSLs containing
DPPC, which possesses a phase transition temperature of 41.9°C. The anticancer activity of
DOX-loaded TSL can be further enhanced by modifying the surface of TSL with cRGD ligands
that bind to αVβ3 integrin, which is overexpressed in many cancer cells. The in vivo
accumulation of DOX from a cRGD modified TSL at tumor site was shown to be 5-fold higher
than that from the corresponding non-targeted TSL[98].
1.4.3.3 Ultrasound-sensitive liposomes. Echogenic (ultrasound-triggered) liposomes
(Els) are designed to co-encapsulated air and drug, which allow them to react to ultrasound
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stimuli[99]. The hypothesis to explain it is that the ultrasound waves can cause an air pocket
expansion to disrupt the lipid bilayer. It is possible to obtain a bolus release with only a single
high amplitude ultrasound pulse and a sustained release with a series of low amplitude
pulses[100]. Kee et al. developed a papaverine hydrochloride encapsulated Echogenic liposome
that greatly reduced side effects while maintained the inhibitory activity of the drug[101]. In
another study, a perfluoropentane and DOX co-encapsulated echogenic liposome containing 1,2dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) released 80% of the DOX after low-intensity
ultrasound exposure[102].
1.4.3.4 Magnetic liposomes. Magnetic liposomes (MLs) contain Fe3O4 or γ-Fe2O3 and
are designed to release the cargo drug in response of an external magnetic field[103]. MLs can
be used as diagnostic agents such as MRI contrast agents[104] as well as heat mediators in
hyperthermia therapy that uses an alternating magnetic field[105]. The goal of using MLs in
anticancer therapy is to enhance drug accumulation at the tumor site while reducing the side
effects. Saiyed et al. developed a ML delivery system encapsulating azidothymi-dine 5triphosphate (AZTTP), which elevated the permeability of AZTTP by 3-fold under an external
magnetic stimulus in an in vitro blood brain barrier model of HIV-infected peripheral blood
mononuclear cells[103]. Generally, when a high-frequency alternating magnetic field is applied,
hyperthermia is often triggered as well, which suggests an potential of developing a combined
trigger release system for anticancer therapy[106]. Surface modification by targeting ligands can
improve the affinity of MLs to tumor cells. For example, RGD-coated MLs were prepared to
deliver sodium diclofenac into cerebral inflammatory sites. The resultant delivery system
showed much higher drug distribution in brain than the free drug (9.1 fold), the conventional
RGD-coated liposomes (6.62 fold) and the uncoated ML formulation (1.5 fold)[107].
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1.4.3.5 Light-sensitive liposomes. Light-sensitive liposomes (LSLs) are constructed with
light-sensitive lipids, which trigger the drug release upon exposure to appropriate photon
stimulus. The mechanisms of sensitivity to light include photoisomerization, photocleavage and
photopolymerization[108]. Near-infrared light penetrates deeper into tissues than UV and visible
light, and is thus more desirable for tumor treatment. One of the most used light-sensitive lipid
is the meta-tetra (hydroxyphenyl) chlorin (mTHPC), which is a component of the approved
formulation Foscan® for palliative treatment of advanced squamous cell carcinoma[109]. As
another example, an LSL system containing DPPC, 1,2-didecanoyl-sn-glycero-3-phosphocholine
(DCPC) and DSPE-PEG (2000) was developed for DOX delivery, where DOX was released
after laser exposure at 514 nm to enhance cancer cell death[110]. Gold-coated liposomes were
evaluated as both thermo- and light- sensitive systems because of they can absorb near-infrared
light irradiation to generate heat, which in turn triggers their leakage[111]. One of such
liposome system that was reported in 2014 demonstrated more rapid DOX release than the
control groups[112].
1.5 Hypothesis
Based on the foregoing review of the literature, we hypothesize that incorporation of pHsensitive flipids with long saturated lipid tails can improve the anticancer activities of stealth
liposomes. Accordingly, a series of new flipids carrying a pH-sensitive conformational switch
are proposed and prepared. The corresponding PEGylated pH-sensitive liposomes (fliposomes)
are prepared as an anticancer drug delivery system to deliver doxorubicin. The proposed
fliposomes are characterized in both 2D monolayer cancer cells and in 3D MCS of cancer cells
in culture.
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Design of pH-Sensitive Lipids with a Conformational Switch to Improve the
Anticancer Activities of their Liposome Formulations

2.1 Introduction: Strategies of pH-triggered Release Liposomes
pH-sensitive liposomes are designed to release the encapsulated cargo in response to the
pH change in the surrounding. It is well known that tumors carry lower pH than normal tissues
because of their lower level of oxygen and hence higher level of glycolysis from anaerobic
metabolism. It is reported the pH in tumors ranges from 5.7 to 7.8 compared to the pH around
7.4 in most other tissues[113, 114]. Furthermore, at subcellular level the pH in endosomes and
lysosomes can reach as low as 4.5-5.5[115]. This variety of pH provides a great opportunity in
developing delivery systems that are sensitive to pH changes to achieve a better therapeutic
efficiency against cancer.
Various strategies for constructing pH-sensitive liposomes have been reported. Their
mechanisms of triggered release mainly depend upon acid-induced destabilization of lipid
bilayers. Most pH-sensitive liposomes fall into four categories based on their components and
mechanism[95]. The first category uses a combination of polymorphic lipids and unsaturated
phosphatidylethanolamine (PE), such as diacetylenic-phosphatidyl-ethanolamine (DAPE),
palmitoyl-oleoyl-phosphatidyl-ethanolamine (POPE) and dioleoyl-phosphatidyl-ethanolamine
(DOPE)[116]. At lowered pH the anionic headgroups of the polymorphic lipids become
protonated and decrease in size, which then destabilizes the liposome[117]. The second
category of pH-sensitive liposomes contain “cage” lipid derivatives of PE or annular lipid with
alkyl ether[118]. Such liposomes can reversibly form non-bilayer phase that releases the
encapsulated liposome contents. The third category of liposomes contain synthetic fusogenic
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peptides or proteins. The pH-sensitive peptides or proteins, such as GALA, are stable at neutral
pH, but can promote the fusion between the liposome bilayer and cell membrane at lowered
pH[119]. The fourth category of pH-sensitive liposomes are constructed with pH-sensitive
polymers. The commonly used polymers for this purpose include poly (alkyl acrylic acid)s,
succinylated PEG, and N-isopropylacrylamide (NIPAM) copolymers[120], which can interact
with the lipid membranes in response to pH stimulation to induce the fusion between liposomes
and endosomes[121].
Many applications of pH-sensitive liposomes have been reported to deliver various cargo
molecules to different target sites (Figure 2.1).

Figure 2.1. Clinical applications of pH-sensitive liposomes[95]
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2.2 Design of pH-sensitive Lipids with a Conformational Switch
Another strategy to render liposomes pH-sensitive has been reported by our group and
collaborators[122, 123]. A pH-sensitive lipid was developed with a trans-2-aminocyclohexanl
ring that undergoes a conformational switch upon protonation. This conformational switch can
perturb the lipid bilayer to release the liposome content (Figure 2.2). The lipids with this kind of
conformational switch are named “flipids” and the liposomes containing the flipids are called
“fliposomes”[123-125]. Flipids with different head groups and hydrocarbon tails were designed
and synthesized. The pH-sensitivity of fliposomes were evaluated and the conformational switch
of the flipids in response to the pH change was verified by NMR titration. In this study, a series
of flipids with saturated long hydrocarbon tails and different head groups of estimated pKa of 2.6
– 8.5 are designed and synthesized.

Figure 2.2. Perturbation of lipid bilayer by an acid-induced conformational switch
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2.3 Materials and Methods
2.3.1 Materials. Fumaryl chloride, 1-hexadecanol, Butadiene sulfone, Hydroquinone,
Azetidine, Pyrrolidine and Ethylamine were purchased from Sigma-Aldrich. metaChloroperoxybenzoic acid (m-CPBA), 2,2,2-trifluoroethylamine, morpholine, 3aminopropionitrile, copper (II) tetrafluoroborate were purchased from Thermo Fisher Scientific.
All organic solvents were purchased from Sigma, Fisher or VWR.
2.3.2 Synthesis of pH-sensitive lipids with a conformational switch (flipids). Trans-2aminocyclohexanol-based amphiphiles were synthesized using the previously described
method[126] (Scheme 2.1). 1H-NMR were acquired with a JEOL ECA 600 MHz FT-NMR
spectrometer (Redding, CA, USA). High resolution mass spectra were acquired by with a JEOL
Accu-TOF LC time of flight mass spectrometer (JEOL, Peabody, MA, USA) equipped with a
DART ion source (IonSense, Saugus, MA, USA).
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Scheme 2.1. Synthesis of pH-sensitive lipids with a conformational switch[126]

Dihexadecyl fumarate:
COO(CH 2)15CH 3

H3C(H 2C)15OOC

Fumaryl chloride (3.22g, 20 mmol) was refluxed for 12 h with 10.2 g (42 mmol) of 1hexadecanol in 30 ml of dry chloroform. The reaction mixture was diluted with 60 mL of
CH2Cl2 and washed with 2 × 20 mL NaOH (5% sol). The organic layer was washed with 2 × 10
mL of hydrochloric acid (5% sol), 10 mL of brine, dried over CaCl2 and concentrated in vacuo.
The residue was purified by column chromatography (Hexane: EtOAc, 60:1) to yield 6.7g (60%)
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of oily solid. Rf: 0.33 (Hexane: EtOAc, 60:1). 1H NMR (600 MHz, CDCl3): δ 0.86 (t, J = 6.9
Hz, 6H, CH3), 1.19-1.37 (m, 52H, CH2, hexadecyl), 1.65 (quin, J = 6.7 Hz, 4H, CH2, hexadecyl),
4.17 (t, J = 6.7 Hz, 4H, COOCH2), 6.824 (s, 2H, HC=CH). HRMS: C36H68O4 requires m/z
[M+H]+ 565.5196, found 565.5135.
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Dihexadecyl 4-cyclohexene-trans-1,2-dicarboxylate:
COO

COO

Butadiene sulfone (2.0 g, 17.3 mmol, 50% excess), dihexadecyl fumarate (6.5g, 11.5
mmol) and hydroquinone (86 mg, 0.8 mmol) were mixed and diluted with 20 mL of isopropyl
alcohol. The mixture was heated in a sealed reactor at 120oC for 48 h. After cooling down, the
reaction mixture was combined with, 120 mL of H2O and 90 mL of CHCl3 and then neutralized
by stirring with crystalline NaHCO3 (~35g). The organic layer was separated, washed with 2 ×
40 mL of water and 60 mL of brine, dried over CaCl2 and concentrated in vacuo. The residue
was further purified by column chromatography (Hexane: EtOAc, 60:1) to yield 5.3g (71%) of
white solid. Rf: 0.36 (Hexane: EtOAc, 40:1). 1H NMR (600 MHz, CDCl3): δ 0.86 (t, J = 7.1
Hz, 6H, CH3), 1.19-1.37 (m, 52H, CH2, hexadecyl), 1.59 (br. quin, J = 6.8 Hz, 4H, CH2,
hexadecyl), 2.11-2.21 (m, 2H, H3a+H6a), 2.36-2.46 (m, 2H, H3e+H6e), 2.84 (m, 2H, H1+H2),
4.055 (m, 4H, COOCH2), 5.67 (m, 2H, H4+H5). HRMS: C40H74O4 requires m/z [M+H]+
619.5665, found 619.5644.
Dihexadecyl 7-oxabicyclo[4.1.0]heptane-trans-3,4-dicarboxylate:
COO
O
COO

Dihexadecyl 4-cyclohexene-trans-1,2-dicarboxylate (5 g, 8 mmol) was dissolved in 15
mL of dry CH2Cl2, and m-CPBA (3 g of 70 % tech. grade, 12 mmol) was added in small
portions at 0 ℃ while stirring. The reaction mixture was kept at this temperature for 14 h. After
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the consumption of the starting material (TLC, Hexane: EtOAc, 20:1), 30 mL of chloroform was
added followed by 40 mL of saturated Na2CO3. The mixture was stirred for 30 min and then the
organic phase was washed with 4 x 20 mL of Na2CO3. The organic layer was dried for 12 h over
anhydrous Na2SO4 and concentrated in vacuo. The residue was isolated as a white solid by
column chromatography (Hexane: EtOAc, 12:1): yield 4.2 g (82 %). Rf: 0.31 (Hexane: EtOAc,
8:1). 1H NMR (600 MHz, CDCl3): δ 0.854 (t, J = 7.0 Hz, 6H, CH3), 1.17-1.37 (m, 52H, CH2,
hexadecyl), 1.57 (m, 4H, CH2, hexadecyl), 1.87 (ddd, J = 14.9, 10.8, 2.1 Hz, 1H, H5a), 2.034
(dd, J = 15.5, 10.8 Hz, 1H, H2a), 2.29 (ddd, J = 15.5, 6.6, 4.8 Hz, 1H, H2e), 2.44 (ddd, J = 14.9,
4.8, 1.8 Hz, 1H, H5e), 2.59 (dt, J = 6.6, 10.7 Hz, 1H, H3), 2.814 (dt, J = 4.9, 10.6 Hz, 1H, H4),
3.16 (t, J = 4.3 Hz, 1H, H1), 3.23 (dt, J = 3.8, 1.9 Hz, 1H, H6), 4.03 (m, 4H, COOCH2). HRMS:
C40H74O5 requires m/z [M+H]+ 635.5615, found 635.5548.
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Dihexadecyl cis-4-hydroxy-trans-5-(2,2,2-trifluoroethylamino)cyclohexane-trans-1,2dicarboxylate:
F3C
HN

COO

HO

COO

Dihexadecyl 7-oxabicyclo[4.1.0]heptane-trans-3,4-dicarboxylate (0.45 g, 0.71 mmol) and
2,2,2-Trifluoroethylamine (0.56 mL, 7.1 mmol) were stirred for 3 days with the catalyst
Copper(II) tetrafluoroborate hexahydrate (24.52 mg, 0.071 mmol) at room temperature in 2 mL
of THF. The reaction mixture was concentrated on a rotary evaporator. The residue was isolated
as a white solid by column chromatography (Hexane: EtOAc, 5:1): yield 0.34 g (66.1%). Rf:
0.25 (Hexane: EtOAc, 4:1). 1H NMR (600 MHz, CD3OD): δ 0.87 (t, J = 7 Hz, 6H, CH3), 1.201.39 (m, 52H, CH2, hexadecyl), 1.6 (m, 4H, CH2, hexadecyl), 1.78 (dt, J = 13.7, 4.1 Hz, 1H,
H6e), 1.82 (dt, J = 13.7, 4.1 Hz, 1H, H3e), 1.94 (m, 1H, H6a), 1.96 (m, 1H, H3a), 2.78 (q, J =
3.8 Hz, 1H, H5), 2.99 (dt, J = 3.6, 9.6 Hz, 1H, H1), 3.01 (dt, J = 4, 9.8 Hz, 1H, H2), 3.22 (m, 2H,
CH2N), 3.73 (dt, J = 2.9, 4.6 Hz, 1H, H4), 4.05 (m, 4H, COOCH2). HRMS: C42H78F3NO5
requires m/z [M+H]+ 734.5832, found 734.5798.

55

56
Dihexadecyl cis-4-hydroxy-trans-5-morpholinocyclohexane-trans-1,2dicarboxylate[127]:

O
N

COO

HO

COO

Dihexadecyl 7-oxabicyclo[4.1.0]heptane-trans-3,4-dicarboxylate (0.45 g, 0.71 mmol) and
morpholine (0.62 mL, 7.1 mmol) were stirred for 2 days with the catalyst Copper(II)
tetrafluoroborate hexahydrate (24.52 mg, 0.071 mmol) at room temperature in 2 mL of THF.
The reaction mixture was concentrated on a rotary evaporator. The residue was isolated as a
white solid by column chromatography (Hexane: EtOAc, 5:1): yield 0.41 g (79.4%). Rf: 0.35
(Hexane: EtOAc, 3:1). 1H NMR (600 MHz, CD3OD): δ 0.89 (t, J = 7.1 Hz, 6H, CH3), 1.23-1.40
(m, 52H, CH2, hexadecyl), 1.62 (br. quin, J = 6.9 Hz, 4H, CH2, hexadecyl), 1.79 (ddd, J = 13.4,
5.0, 4.8 Hz, 1H, H3e), 1.89 (ddd, J = 14.1, 5.4, 3.9 Hz, 1H, H6e), 2.00 (m, 1H, H6a), 2.02 (m,
1H, H3a), 2.23 (dt, J = 3.0, 5.3 Hz, 1H, H5), 2.49 (m, 2H, CH2N, morpholyl), 2.57 (m, 2H,
CH2N, morpholyl), 2.98 (dt, J = 3.6, 9.5 Hz, 1H, H1), 3.08 (dt, J = 4.4, 9.5 Hz, 1H, H2), 3.70 (m,
4H, OCH2, morpholyl), 4.00 (dt, J = 2.8, 5.2 Hz, 1H, H4), 4.07 (m, 4H, COOCH2). HRMS:
C44H83NO6 requires m/z [M+H]+ 722.6299, found 722.6113.
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Dihexadecyl cis-4-hydroxy-trans-5-(2-cyanoethylamino)cyclohexane-trans-1,2dicarboxylate:

NC

HN

COO

HO

COO

Dihexadecyl 7-oxabicyclo[4.1.0]heptane-trans-3,4-dicarboxylate (0.45 g, 0.71 mmol) and
3-Aminopropionitrile (0.52 mL, 7.1 mmol) were stirred for 3 days with the catalyst Copper(II)
tetrafluoroborate hexahydrate (24.52 mg, 0.071 mmol) at room temperature in 2 mL of THF.
The reaction mixture was concentrated on a rotary evaporator. The residue was isolated as a
white solid by column chromatography (Hexane: EtOAc, 3:1): yield 0.36 g (71.2%). Rf: 0.31
(Hexane: EtOAc, 3:1). 1H NMR (600 MHz, CD3OD): δ 0.88 (t, J = 7 Hz, 6H, CH3), 1.20-1.42
(m, 52H, CH2, hexadecyl), 1.6 (m, 4H, CH2, hexadecyl), 1.75 (dt, J = 13.9, 4.6 Hz, 1H, H6a),
1.82 (dt, J = 11.8, 4.3 Hz, 1H, H3a), 1.98 (m, 2H, H6e+H3e), 1.99 (s, 1H, NH), 2.57 (m, 3H,
H5+CH2CN), 2.72 (q, J = 4.3 Hz, 1H, H1), 2.85 (dt, J = 12.2, 6.9 Hz, 1H, CH2N), 2.94 (dt, J =
14.3, 6.8 Hz, 1H, CH2N), 2.99 (td, J = 10.3, 3.7 Hz, 1H, H2), 3.04 (td, J = 9.4, 4.3 Hz, 1H, H4),
4.05 (m, 4H, COOCH2). HRMS: C43H80N2O5 requires m/z [M+H]+ 705.6067, found 705.6085.
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Dihexadecyl cis-4-hydroxy-trans-5-(azetidine-1-yl)cyclohexane-trans-1,2dicarboxylate:

N

COO

HO

COO

Dihexadecyl 7-oxabicyclo[4.1.0]heptane-trans-3,4-dicarboxylate (0.45 g, 0.71 mmol) and
azetidine (0.48 mL, 7.1 mmol) were stirred for 3 days with the catalyst Copper(II)
tetrafluoroborate hexahydrate (24.52 mg, 0.071 mmol) at room temperature in 2 mL of THF.
The reaction mixture was concentrated on a rotary evaporator. The residue was isolated as a
white solid by column chromatography (Hexane: EtOAc, 5:1): yield 0.39 g (78.8%). Rf: 0.35
(Hexane: EtOAc, 4:1). 1H NMR (600 MHz, CD3OD): δ 0.88 (t, J = 7 Hz, 6H, CH3), 1.20-1.38
(m, 52H, CH2, hexadecyl), 1.6 (br. quin, J = 7 Hz, 4H, CH2, hexadecyl), 1.71 (m, 2H,
H6e+H3e), 1.83 (m, 2H, H6a+H3a), 2.04 (quin, J = 7 Hz, 2H, CH2CH2N), 2.31 (dt, J = 3.4, 3.3
Hz, 1H, H5), 2.89 (td, J = 10.3, 5 Hz, 1H, H1), 2.95 (td, J = 10.8, 5.3 Hz, 1H, H2), 3.21 (ddd, J =
6.6, 13.2, 23.6 Hz, 4H, CH2CH2N), 3.70 (dt, J = 3.4, 3.2 Hz, 1H, H4), 4.03 (m, 4H, COOCH2).
HRMS: C43H81NO5 requires m/z [M+H]+ 692.6114, found 692.6121.
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Dihexadecyl cis-4-hydroxy-trans-5-(pyrrolidine-1-yl)cyclohexane-trans-1,2dicarboxylate:

N

COO

HO

COO

Dihexadecyl 7-oxabicyclo[4.1.0]heptane-trans-3,4-dicarboxylate (0.45 g, 0.71 mmol) and
pyrrolidine (0.59 mL, 7.1 mmol) were stirred for 4 days with the catalyst Copper(II)
tetrafluoroborate hexahydrate (24.52 mg, 0.071 mmol) at room temperature in 2 mL of THF.
The reaction mixture was concentrated on a rotary evaporator. The residue was isolated as a
white solid by column chromatography (Hexane: EtOAc, 5:1): yield 0.28 g (56.2%). Rf: 0.32
(Hexane: EtOAc, 4:1). 1H NMR (600 MHz, CD3OD): δ 0.88 (t, J = 7.1 Hz, 6H, CH3), 1.20-1.40
(m, 52H, CH2, hexadecyl), 1.6 (m, 4H, CH2, hexadecyl), 1.77 (quin, J = 2.8 Hz, 4H, CH2,
CH2CH2N), 1.87 (m, 2H, H6e+H3e), 1.93 (m, 2H, H6a+H3a), 2.21 (m, 1H, H5), 2.53 (m, 2H,
CH2CH2N), 2.60 (m, 2H, CH2CH2N), 2.95 (td, J = 10.4, 4.4 Hz, 1H, H1), 3.01 (td, J = 11.0, 5.1
Hz, 1H, H2), 4.01 (m, 1H, H4), 4.03 (m, 4H, COOCH2). HRMS: C44H83NO5 requires m/z
[M+H]+ 706.6271, found 706.6276.
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Dihexadecyl cis-4-hydroxy-trans-5-(ethylamino)cyclohexane-trans-1,2-dicarboxylate:

HN

COO

HO

COO

Dihexadecyl 7-oxabicyclo[4.1.0]heptane-trans-3,4-dicarboxylate (0.45 g, 0.71 mmol) and
ethylamine (0.46 mL, 7.1 mmol) were stirred for 4 days with the catalyst Copper(II)
tetrafluoroborate hexahydrate (24.52 mg, 0.071 mmol) at room temperature in 2 mL of THF.
The reaction mixture was concentrated on a rotary evaporator. The residue was isolated as a
white solid by column chromatography (Hexane: EtOAc, 1:1): yield 0.3 g (62.7%). Rf: 0.21
(Hexane: EtOAc, 2:3). 1H NMR (600 MHz, CD3OD): δ 0.88 (t, J = 7.0 Hz, 6H, CH3), 1.12 (t, J
= 7.1 Hz, 3H, CH3, ethylamino), 1.21-1.40 (m, 52H, CH2, hexadecyl), 1.61 (m, 4H, CH2,
hexadecyl), 1.71 (ddd, J = 13.5, 6.0, 4.1 Hz, 1H, H6e), 1.78 (ddd, J = 13.8, 6.4, 4.6 Hz, 1H, H3e),
2.01 (m, 1H, H3a), 2.05 (m, 1H, H6a), 2.58 (dq, J = 11.4, 7.0 Hz, 1H, CH2N), 2.66 (dt, J = 4.0,
5.7 Hz, 1H, H5), 2.72 (dq, J = 11.5, 7.2 Hz, 1H, CH2N), 3.01 (td, J = 8.8, 4.0 Hz, 1H, H1), 3.08
(td, J = 8.6, 4.4 Hz, 1H, H2), 3.69 (dt, J = 2.9, 10.9 Hz, 1H, H4), 4.05 (m, 4H, COOCH2).
HRMS: C44H83NO5 requires m/z [M+H]+ 680.6114, found 680.6105.
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2.4 Results and Discussion
The products from each step was confirmed with MS and NMR studies. The final
products of each pH-sensitive flipid were sent out to Complete Analysis Laboratories. Inc.
(Highland Park, NJ, USA) to perform an elemental analysis (C, H, N). The results are listed in
Table 2.1. The accepted deviation of the results from the calculated is 0.4% according to ACS
standard[128] which is achieved by all samples.

Table 2.1. Elemental Analysis of C16 flipids
Sample
Eth-C16
Pyr-C16
Aze-C16
Ami-C16
Mor-C16
Tri-C16

Calculated
C%
74.17
74.84
74.62
73.25
73.18
69.04

Measured
C%
74.06
74.94
74.78
73.39
73.26
68.66

Error
0.11
-0.10
-0.16
-0.14
-0.08
0.38

Calculated
H%
12.00
11.85
11.8
11.44
11.58
10.78

Measured
H%
12.11
12.03
11.94
11.51
11.58
10.82

Error
-0.11
-0.18
-0.14
-0.07
0.00
-0.04

Calculated
N%
2.06
1.98
2.02
3.97
1.94
1.87

Measured
N%
2.11
2.24
2.11
4.17
2.24
2.03

Error
-0.05
-0.26
-0.09
-0.20
-0.30
-0.16

One important physicochemical property of the lipids is the phase transition temperature
(Tm). It is defined as the temperature required to induce a change in the lipid physical state from
the ordered gel phase to the disordered liquid crystalline phase[129]. It has a direct impact on
the stability of liposomes where the entrapped material shows low permeability below Tm and an
increase of permeability above Tm. There are several factors that directly affect Tm such as the
polar head group, acyl chain length, degree of saturation of the hydrocarbon chains and the
properties (e.g. ionic strength) of the suspension medium[130]. As the hydrocarbon length of
the lipid tail increases, the van der Waals interactions between the lipid molecules get stronger to
yield higher Tm. Introducing an unsaturated bond in the hydrocarbon chain decreases the energy
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needed to disrupt the lipid tail packing to yield a lower Tm. Sufficient stability in blood
circulation at 37°C is the required of a liposome delivery system for clinical applications. Table
2.2 shows five phospholipids with different Tm. From the table we can see that a saturated lipid
with at least 16 hydrocarbon chain can be ideal for a liposome formulation in the clinic.

Table 2.2. Transition Temperature of Phospholipids[131]
Lipid
DLPC
DMPC
DPPC
DSPC
DOPC

Hydrocarbon length
12
14
16
18
18

Unsaturated bond
0
0
0
0
1

Tm (°C)
-1
23
41
55
-20

Previous studies showed that the pKa of flipids were determined by the structure of
hydrophilic head groups[122]. To cover the pH range of solid tumor (pH 6.5-7.2) and endosome
(5.0-6.5), six amino headgroups were chosen based on the estimated pKa value from titration
curves of previous studies[122, 126]. The structure features of the newly designed flipids under
my dissertation studies are summarized in Table 2.3.

Table 2.3. Flipids with Saturated C16 Hydrocarbon Tail and Different Amino Head Groups
Designed for Studies for this Dissertation.
Name of flipids
Eth-C16
Pyr-C16
Aze-C16

Head Group
Ethylamine
Pyrrolidine
Azetidine

Hydrocarbon Tail
Saturated C16
Saturated C16
Saturated C16

Estimated pKa
8.5
7.6
6.8
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Ami-C16
Mor-C16
Tri-C16

Aminopropionitrile
Morpholine
Trifluoroethylamine

Saturated C16
Saturated C16
Saturated C16

5.6
4.9
2.6

The chemical synthesis of the designed lipids is summarized in Scheme 2.1. Briefly,
Fumaryl chloride was refluxed with 1-hexadecanol in dry chloroform during an alcoholysis
reaction. Then the purified product dihexadecyl fumarate was heated with butadiene sulfone in a
sealed reactor at 120°C for 48 h. After purification the resulted compound was mixed with mCPBA in dry CH2Cl2 at 0°C under stirring. The reaction was completed to yield epoxide in 14 h
and the product was purified. Lastly, the designed lipids were obtained by mixing epoxide with
different amines and the catalyst Copper (II) tetrafluoroborate hexahydrate for 2 – 4 days. The
synthesis is based on the previously reported syntheses of similar flipids[122, 124] but carries an
important modification of employing a catalyst in the epoxide ring-opening reaction in the last
step. This nucleophilic addition reaction under previously reported conditions without the
catalyst was very slow with low yields on the epoxides with C14 hydrocarbon chains. The
reaction was found to be even slower on the epoxides with longer hydrocarbon chains. For
example, Ditetradecyl cis-4-hydroxy-trans-5-morpholinocyclohexane-trans-1,2-dicarboxylate
(C14) was prepared at a 59% yield after 5 days stirring the epoxide with morpholine in room
temperature while the dihexadecyl cis-4-hydroxy-trans-5-morpholinocyclohexane-trans-1,2dicarboxylate (C16) was made only at a 21.1% yield after 5 days reaction and 39.8% yield after
10 days reaction at room temperature. It has been reported that Copper (II) tetrafluoroborate can
be used as a catalyst for epoxide ring-opening reactions to boost the yield and reduce the
reaction time[127]. Including this catalyst at an appropriate molar ratio (epoxide: amine: catalyst
= 1 : 10 : 0.1) resulted in a much higher yield of 76.2% after 2 days of reaction at room
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temperature for dihexadecyl cis-4-hydroxy-trans-5-morpholinocyclohexane-trans-1,2dicarboxylate (C16).
The yields of six designed flipids in the last step of nucleophilic addition are summarized
in Table 2.4. All the flipids were successfully synthesized with relatively high yields within 2 –
4 days.

Table 2.4. Yield of Designed Flipids
Flipids
Yield (%)

Eth-C16
62.7

Pyr-C16
56.2

Aze-C16
78.8

Ami-C16
71.2

Mor-C16
79.4

Tri-C16
66.1
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Preparation and Characterization of pH-sensitive Fliposome

3.1 Introduction on Strategies to Prepare Liposomes
When amphiphilic molecules are placed in aqueous environment, they tend to form
aggregated complexes in order to shield their hydrophobic moieties from water molecules while
maintaining contact with the aqueous phase with their hydrophilic moieties. The formation of
liposomes is not a spontaneous process. It requires sufficient amount of energy (sonication,
homogenization, heating, etc.) to achieve a thermodynamic equilibrium and to form organized,
closed bilayer vesicles[132]. Typically, liposomes can be prepared using mechanical dispersion
methods or solvent dispersion methods[133, 134].
The mechanical dispersion methods involve the following procedures: lipid film
hydration, sonication, freeze-thawing, and membrane extrusion. When liposomes are prepared
with mixed lipids, the lipids must first be dissolved as a homogenous mixture in an organic
solvent. The solvent is then to be removed under vacuum to yield a lipid film. Lipid film
hydration is accomplished by adding a hydration buffer above the lipid transition temperature
(Tm). A bath or probe tip sonicator is usually used for producing small unilamellar vesicles
(SUV) with diameters in the range of 15-50 nm. The main disadvantages of sonication are low
internal volume, low encapsulation efficacy and possible degradation of the lipids and
encapsulated contents[134]. The process of freezing and thawing results in unilamellar vesicles
by inducing the fusion of SUV[135, 136]. Extrusion is a process in which micrometric
liposomes are extruded using polycarbonate filters with different pore size to yield liposomes of
a smaller size. This process should be carried out above the transition temperature of the lipids.
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Three commonly used methods of solvent dispersion for liposome preparation are ether
injection, ethanol injection and reverse phase evaporation[133]. The ether injection method
involves gradually injecting an ether solution of lipids into aqueous buffer at 55°C to 65°C or
under reduced pressure. The elevated temperature or the reduced pressure removes ether to form
the liposomes. The ethanol injection method involves rapidly injecting an ethanol solution of
lipids into a much larger volume of aqueous buffer. Liposomes are formed upon the dilution of
the ethanol, which can then be removed by dialysis. The disadvantage of both the ether injection
method and the ethanol injection method is that the resultant population of liposomes is
heterogeneous. The reverse phase evaporation method is based on the conversion of inverted
micelles of lipid-coated organic solvent molecules in aqueous buffer into a viscous gel by
evaporating the organic solvent. When the gel eventually collapses, some of the phospholipids
form bilayer structures around the residual micelle to form liposomes[133]. Liposomes made
from this method usually have a higher aqueous space-to-lipid ratio[137] than other methods of
liposome preparation.
In this study, mechanical dispersion methods were used for liposome preparation due to
the well-established procedures in our group. The preparation involved lipid film hydration,
freeze-thawing, and membrane extrusion. The sonication was avoided in order to form
liposomes with relatively high internal volume and encapsulation efficacy.
3.2 Materials and Methods
3.2.1 Materials. The lipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), Npalmitoyl-sphingosine-1-(succinyl[methoxy(polyethylene glycol)2000]) (PEG-ceramide), 1,2dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000 (DPPEPEG (2000)) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Cholesterol
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was purchased from Fisher. Doxorubicin Hydrochloride was purchased from Biotang (Waltham,
MA, USA). Calcein was purchased from Thermo Fisher Scientific. 2-[4-(2hydroxyethyl)piperazin-1-yl]-ethanesulfonic acid (HEPES), octaethylene glycol monododecyl
ether (detergent C12E8) and all other chemicals were purchased from Sigma, Fisher or VWR.
3.2.2 Preparation of liposome.
3.2.2.1 Preparation of DOX-loaded liposome. Lipids were dissolved in dichloromethane
or chloroform as stock solutions. Liposomes were prepared using the thin-film hydration
technique based on prior reports[122, 123]. Ratios of lipid components were in mole units.
Lipids of different compositions (Table 3.1) were mixed in a pear-shaped recovery flask. The
solvent was removed by a rotary evaporator to form a thin film at the bottom of the flask. The
lipid film was further dried in a vacuum for at least four hours before hydration with 30 mM
HEPES buffer (pH 7.4) containing 300 mM MnSO4 in a 60 °C water bath. The flask was filled
with argon and sealed with parafilm. The total lipid concentration was 20 mM. After all the
lipid film was detached from the flask, the milky liposome suspension was then sequentially
immerged in liquid nitrogen. The flask was then immerged in ice-and-water mixture for two
minutes before being immerged back in 60 °C water bath until the temperature was equilibrated.
Thee freeze-thawing process was repeated seven times. Then the liposome suspension was
extruded twenty-one times each through polycarbonate membrane with pores of 400, 200 and
100 nm in diameter (Nucleopore, Pleasanton, CA, USA) sequentially, using a hand-held
extrusion device (Avanti Polar Lipids, Alabaster, AL, USA). The resultant liposome suspension
was run through a Sephadex G-75 size exclusion column pre-equilibrated with 5 mM HEPES
and 145 mM NaCl at pH 7.4 to remove the unencapsulated manganese sulfate and thus to
establish the transmembrane manganese sulfate gradient. Doxorubicin was dissolved in the same
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5 mM HEPES and 145 mM NaCl buffer at pH 7.4 to a concentration of 4 mM. The solution was
then mixed with the liposomes carrying the transmembrane manganese sulfate gradient in 1:1
volume ratio and incubated at 60 °C for 50 minutes [138]. The unencapsulated doxorubicin was
then removed by gentle shaking with Dowex® Resins (prewashed with 2 M NaOH and
equilibrated with 1 M NaCl[139], resin: Doxorubicin = 60 :1, wt : wt) for 25 minutes. The
resultant liposome preparations were stored at 4 °C in brown glass vials that were filled with
argon until further studies.

Table 3.1. Lipid Compositions of pH-Sensitive Fliposomes A-F and non pH-Sensitive Control
Liposome G
Liposome
molar %
Tri-C16
Mor-C16
Ami-C16
Aze-C16
Pyr-C16
Eth-C16
DPPC
PEG-Ceramide
Cholesterol

A

B

C

D

E

F

G

25
x
x
x
x
x
70
5
x

x
25
x
x
x
x
70
5
x

x
x
25
x
x
x
70
5
x

x
x
x
25
x
x
70
5
x

x
x
x
x
25
x
70
5
x

x
x
x
x
x
25
70
5
x

x
x
x
x
x
x
55
5
40

3.2.2.2 Preparation of liposomes encapsulating calcein. DPPC, Mor-C16 TACH lipid,
PEG-Ceramide (70: 25: 5) and DPPC, Cholesterol, PEG-Ceramide (55: 40: 5) were mixed in a
pear-shaped recovery flask. The solvent was removed by a rotary evaporator to form a thin film
at the bottom of the flask. The lipid film was further dried in a vacuum for at least four hours
before hydration with 100 mM Calcein (pH 7.4) in a 60 °C water bath, when the flask kept filled
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with argon and sealed with parafilm. The total lipid concentration was 20 mM. After all the
lipid film was detached from the flask, the liposome suspension was immerged sequentially in
liquid nitrogen, ice-and-water mixture for two minutes, and back in a 60 °C water bath until the
temperature was equilibrated. The freeze-thawing process was repeated seven times. Then the
liposome suspension was extruded twenty-one times each through polycarbonate membranes
with pores at 400, 200 and 100 nm in diameter (Nucleopore, Pleasanton, CA, USA) sequentially,
using a hand-held extrusion device (Avanti Polar Lipids, Alabaster, AL, USA). The resultant
liposome suspension was passed through a Sephadex G-75 size exclusion column preequilibrated with 5 mM HEPES and 145 mM NaCl at pH 7.4 to remove the unencapsulated
calcein. The liposome preparations were stored at 4°C in brown glass vials that were filled with
argon.
3.2.3 Physicochemical characterizations of fliposomes. The sizes and ζ-potential of
the liposome formulations were measured using a Malvern Zeta 3000 Photon Correlation
Spectrometry instrument (Malvern Instruments Ltd., Worcestershire, UK).
3.2.4 Encapsulation efficiency of fliposomes. An aliquot (10 µL) of DOX-loaded
liposome was mixed with 190 µL lysing buffer containing 90% isopropanol and 0.075 M
HCl[140]. The fluorescence of DOX was read on a fluorometric 96 well plate reader (Ex. = 485
nm and Em. = 590 nm). The concentration of DOX was quantified from a calibration curve of
DOX standard solutions (1, 2, 5, 10, 20, 50, 100 µg/ml). The encapsulation efficiency of DOXloaded liposome can be determined by the ratio of the amount of encapsulated DOX and the
amount of DOX incubated with the liposome for the drug-loading.
3.2.5 pH-Triggered release of fliposomes.
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3.2.5.1 pH-Triggered release of DOX-loaded fliposomes. Four buffers of different pH
were prepared as the following: pH 7.4 (100 mM HEPES, 92.6 mM glucose), pH 7.0 (100 mM
HEPES, 92.6 mM glucose), pH 6.5 (100 mM MES, 92.6 mM glucose), pH 6.0 (100 mM MES,
92.6 mM glucose). Liposome formulations were gently shaken with sufficient amount of resin
( resin : Dox = 60 : 1, wt : wt) in each of the four buffers at 37°C. At given time points (0, 1, 3,
6, 12, 24, 36, 72 h, 10 µl of each formulation were transferred into a clear bottom black 96 well
plate containing 190 µl 90% isopropanol with 0.075 M HCl in each well. After 5 minutes of
gentle shaking to fully lyse the liposomes the fluorescence of the released doxorubicin was
measured in a fluorescence 96 plate reader. The fluorescence reading at time zero was
considered as the total encapsulated DOX in each formulation. All measurements were in
triplicates. The amount of doxorubicin was estimated from the calibration curve as described
before and the release percentage was calculated as:
release % = (1 −

𝑀𝑡𝑖𝑚𝑒
) 𝑥 100
𝑀𝑡𝑜𝑡𝑎𝑙

3.2.5.2 pH-Triggered release of calcein-loaded fliposmes. An aliquot (20 µl) of a
liposome formulation was added into 180 µl of a buffer of defined pH at 7.4, 7.0, 6.5 or 6.0 as
described above in a 96 well plate. The plate was incubated at 37°C. At different time points (1,
3, 6, 12, 24, 36, 72 h), the fluorescence of each well was measured on fluorometric 96 well plate
reader (Ex. = 495 nm and Em. = 515 nm). After the fluorescence measurement at the last time
point, 10 µl detergent (C12E8) was added to fully lyse the calcein-loaded liposomes. All
measurements are in triplicates. The release percentage was calculated as following, where Ft is
the fluorescence reading of certain time point and Flast is the fluorescence reading of last time
point.
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release % =

𝐹𝑡
𝑥 100
𝐹𝑙𝑎𝑠𝑡

3.3 Results and Discussion
3.3.1 Lipid compositions in fliposome formulations. We successfully formulated
fliposomes that consisted of flipids, a PEG-Ceramide conjugate and DPPC. The lipid
compositions of such fliposome formulations are listed in Table 3.1. PEG-Ceramide, which
contains a C16 hydrocarbon tail, facilitates the lipid film hydration and is expected to yield longcirculating stealth liposomes[87]. DPPC is a common commercially available lipid that also
contains C16 hydrocarbon tails as in PEG-Ceramide and the flipids to facilitate the mixing of the
lipids in the liposome membrane[141]. Previously flipids with C12 hydrocarbon tails were used
to readily prepare fliposomes consisting of 50 mol% flipids, 45 mol% POPC and 5 mol% PEGCeramide[123], wherein POPC, which carries on saturated and one unsaturated C16 hydrocarbon
chain, is a highly compatible lipid with many types of other lipids to form lipid bilayer[142].
During the preparatioin of fliposomes consisting of saturated C16 filips, the resistance against
liposome extrusion was exceptionally high when 50 mol% flipids were applied, which generated
highly heterogeneous lipid suspensions. The high resistance against extrusion was probably due
to the higher transition temperature and thus less fluidity of the lipid bilayers. As a compromise,
lower mol% of flipids was attempted in this thesis work, which allowed the construction of
fliposomes consisting of 25 mol% of a flipid, 70 mol% DPPC and 5 mol% PEG-Ceramide. A
non pH-sensitive stealth liposome containing 55 mol% DPPC, 40% Cholesterol and 5 mol%
PEG-Ceramide was prepared as a control based on the FDA approved liposomal DOX
formulation Doxil which contains 56.56 mol% fully hydrogenated soy phosphatidylcholine
(HSPC), 38.18 mol% Cholesterol and 5.26 mol% N-(carbonyl-methoxypolyethylene glycol
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2000)-1,2-distearoyl-sn-glycero3-phosphoethanolamine sodium salt (MPEG-DSPE)[143].
HSPC contains two saturated hydrocarbon chains with different length (C16 and C18). MPEGDSPE contains two saturated hydrocarbon chains of C18. In order to compare the pH-sensitivity
of fliposomes with control liposome, HSPC and MPEG-DSPE were replaced with DPPC and
PEG-Ceramide to formulate the control liposome to avoid the influence from the length of the
tails. Cholesterol is a membrane constituent found in many biological systems and widely used
in liposomal formulations[144].
3.3.2 Sizes, ζ-potential and polydispersity index (PDI) of liposome formulations.
After freeze-thawing and extrusion through polycarbonate membranes with 100 nm pores, the
fliposomes showed average sizes smaller than 200 nm. The Polydispersity Index (PDI) of all
formulations were lower than 0.3, indicating homogeneous liposomal suspensions. ζ-potential
are not detectable for all measurements suggesting that liposome formulations are neutral. The
average sizes and PDI of DOX-loaded fliposomes are shown in Table 3.2. The average size of
calcein-loaded Mor-C16 fliposome was 144.3 nm with a PDI of 0.15.

Table 3.2. Size and Polydispersity Index of DOX-loaded Liposomes
Fliposome
Tri-C16/DPPC/PEG-Ceramide

Molar Ratio
25/70/5

Size (nm)
152.2

PDI.
0.126

Mor-C16/DPPC/ PEG-Ceramide

25/70/5

170.5

0.064

Ami-C16/DPPC/ PEG-Ceramide

25/70/5

134.4

0.169

Aze-C16/DPPC/ PEG-Ceramide

25/70/5

119.8

0.165

Pyr-C16/DPPC/ PEG-Ceramide

25/70/5

120.8

0.174
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Eth-C16/DPPC/ PEG-Ceramide

25/70/5

141.1

0.253

Cholesterol/DPPC/PEGCeramide

40/55/5

156.4

0.083

It is well known that the size of drug delivery systems impacts their pharmacokinetics
and tissue distribution[145]. Only nanocarriers with a size lower than 150 nm are able to exit
fenestrated capillaries into the tumor interstitium[146, 147]. However, some literature suggests
that delivery systems below 200 nm in size could take advantage of the EPR effect for passive
targeting to tumor tissues[148, 149]. It is reported that in blood circulation nanocarriers with a
size ranging 100-150 nm do not easily leave the capillaries that perfuse normal tissues in kidney,
lung and heart[145, 150]. Because the fliposomes under this study are all below 200 nm in size
and mostly in the range of 100-150 nm, they could serve as nanocarriers for anticancer drugs.
3.3.3 Encapsulation efficiency (EE) of DOX-loaded fliposomes. As shown in Table
3.3, the encapsulation efficiencies of DOX-loaded fliposomes were in the range of 76% to 100%
with the remote loading method.

Table 3.3. Encapsulation Efficiency of Dox-loaded fliposomes
Fliposome

Molar Ratio

EE (%)

Tri-C16/DPPC/PEG-Ceramide

25/70/5

100

Mor-C16/DPPC/ PEG-Ceramide

25/70/5

100

Ami-C16/DPPC/ PEG-Ceramide

25/70/5
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Aze-C16/DPPC/ PEG-Ceramide

25/70/5

86

Pyr-C16/DPPC/ PEG-Ceramide

25/70/5

95

Eth-C16/DPPC/ PEG-Ceramide

25/70/5
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Remote loading, also known as active loading, was used for loading DOX into flipsomes
because of its higher encapsulation efficiency compared to the passive loading method. Remote
loading relies on a transmembrane gradient to trap the payload molecules inside the liposome
after they diffuse across the liposomal bilayer. Several remote loading methods have been
reported for DOX encapsulation including pH gradient, ammonium sulphate gradient and
manganese gradient[100]. In this project we use manganese gradient for remote loading because
it is compatible with the pH-sensitivity of the fliposomes and is believed to have a higher
encapsulation efficiency based on previous studies[151].
3.3.4 pH-Dependent leakage of fliposomes. We studied the pH-dependent leakage of
fliposomes by measuring their release of DOX and Calcein at pHs 7.4, 7.0, 6.5 and 6.0, 37°C
over time. The pH range of 6.0 - 7.4 was chosen because of the reported pH range of 5.7 - 7.8
inside tumor tissues[113, 114]. The fluorescence of DOX or Calcein was measured and
converted to percentage of release by normalization against the fluorescence of the same sample
after lysing the liposomes with detergent (100% release). pH-triggered release of DOX over 12
h and pH-triggered release of calcein at 12h from fliposomes are showed in Figure 3.1 and 3.2,
respectively.
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Figure 3.1. Release Percentage of DOX-loaded liposomes over 12h at four different pHs, 37°C.
(n=3) The calculated pKa of each flipid is listed beneath the flipid name
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Figure 3.2. pH-Dependent Release of Calcein-loaded Fliposomes over 12h at 37°C. (n=3)
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Figure 3.1 shows that several flipids under this study showed enhanced release as the pH
decreased compared to the control liposome group. This result is consistant with the proposed
mechanism of the pH-sensitivity of the flipids and the fliposomes: upon protonation the
formation of an intramolecular hydrogen bond between the nitrogen of the amino group and the
oxygen of the hydroxy group triggers a conformational flip of the trans-2-amino-cyclohexanol
moiety, which increases the separation of the two hydrocarbon chains of the lipid tail, which in
turndisrupts the lipid bilayer to trigger the release of the liposome contents[55, 126]. With the
same mechanism, a pH-induced expansion (up to 25%) was observed in Langmuir monolayers
containing flipids with C12 hydrocarbon tails [152].
Among all the flipids under this study, C16 trans-2-morpholylcyclohexanol-based flipid
(Mor-C16) has the lowest release (19.8%) at pH 7.4 and the largest increase of release as the pH
dropped from pH 7.4 to 6.0 (17.9%). The estimated pKa of Mor-C16 flipid is 4.9 based on the
change of signal width in an NMR titration in CD3OD in a previous study[153]. However, the
same study estimated a pKa value of 6.7 for the same flipid in aqueous solution using the
ACD/Labs software. This would explain Mor-C16’s largest enhancement of release in response
to the drop of pH compared to other flipids. The difference of 1.8 ±0.7 units between the two
pKa values may be attributed to the solvent effect, where the more polar water solvent would
favor the protonated, charged form of the flipid more than the less polar CD3OD, thus the higher
pKa in water[153]. A comparison of calculated pKa in water versus NMR-estimated pKa in
CD3OD for all flipids is showed in Table 3.4.
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Table 3.4. NMR-estimated pKa in CD3OD versus Calculated pKa in water of flipids[153]
Flipids
Eth-C16
Pyr-C16
Aze-C16
Ami-C16
Mor-C16
Tri-C16

Estimated pKa
8.5
7.6
6.8
5.6
4.9
2.6

Calculated pKa
9.7
9.4
9.4
7.4
6.7
3.7

The pH-dependent release of Calcein-loaded fliposome consisting of the Mor-C16 flipid
was found to carry the same trend as that of the DOX-loaded fliposome, (Figure 3.3) thus
strongly corroborating the pH-sensitivity of the fliposomes under this study.
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Figure 3.3. pH-Dependent Release of Mor-C16 fliposomes over 12 h at 37°C. (n=3)
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Development of 3D Multi-Cellular Spheroids

4.1 Introduction on 3D multi-cellular spheroids (MCS)
Screening of novel anti-cancer agents are usually performed on cancer cells cultured as
two-dimensional(2D) monolayers. Monolayer cells are easy to propagate and amenable to well
established high-throughput studies. However, 2D cancer cell models inadequately reflect in
vivo tumor growth due to the lack of cell-cell and cell-extracellular matrix (ECM)
interactions[154]. The 2D cells do not provide a complex and dynamic microenvironment that is
essential for the unique functions of tumors, such as cell proliferation, differentiation, migration
and intracellular signal transduction[155-157]. Furthermore, 2D cells may display counterfeit
polarity, cell metabolism and protein expression[158].
3D multicellular spheroids (MCS) have been developed to bridge the gap between
conventional 2D systems and in vivo tumor models. 3D MCS are self-assembled under
conditions where the cancer cells are allowed to grow and interact with their surroundings in
three dimensions. 3D MCS have been proven to better mimic the native and complex tumor
microenvironment[159].
The advantages of 3D MCS in presenting a more physiological platform for drug delivery
include the following:
•

3D MCS have the architecture of tissues in vivo including multicellular arrangement and
extracellular matrix, which are absent in 2D models.

•

The cell-extracellular matrix interactions can be found in 3D MCS, which is important
for the response of cells to drug[160].

84
•

Similar to tissues in vivo, 3D MCS impose diffusional limits to various molecules
including drugs, nutrients, oxygen, and protons.

•

Rare cells such as cancer stem cells can be cultured in small number of cells in 3D MCS
platforms, which is difficult to achieve in conventional 2D cell cultures.

•

3D MCS with a certain size can develop necrotic core, quiescent zone and proliferation
zone due to the oxygen and nutrient gradients. It is one cause of drug resistance and can
be used for accurate testing of drug efficacy[161-163].
It is reported that 3D MCS smaller than 200 µm in diameter mostly include proliferating

cells. When they grow as big as 300 µm in diameter, a normoxic quiescent zone in the middle
can be differentiated with the proliferative zone at the surface. Finally, when 3D MCS are larger
than 500 µm, the formation of necrotic core can usually be observed[164-166]. A typical
configuration of 3D MCS (> 500 µm) with different areas is shown in Figure 4.1.
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Figure 4.1. 3D MCS over 500 µm in diameter[167]

4.2 Introduction on strategies of generating 3D MCS
Many strategies have been developed to generate 3D MCS in vitro. In general, the
techniques of culturing 3D MCS fall into two categories: scaffold techniques and scaffold-free
techniques.
Scaffold techniques utilize engineered scaffolds to provide structural support for cells
growing in 3D. The most widely used scaffold is hydrogels, which mimic the natural
extracellular matrix (ECM) to allow cells to adhere, proliferate, spread and migrate[154, 168].
Hydrogels with interconnected pores enable efficient transport of nutrients and gases. There are
several challenges in this technique such as: batch to batch variation, reproducibility and
heterogeneity of 3D MCS in size and shape[167].
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Scaffold-free techniques have been developed to generate 3D MCS without scaffold
support in different kinds of mechanisms. The most commonly used methods include liquid
overlay, hanging drop, spinner flask cultures, rotary cell cultures (Figure 4.2) and ultra-low
attachment (ULA) plates.

Figure 4.2. Scaffold-free methods for MCS formation. (a) liquid overlay, (b) hanging drop, (c)
spinning flask cultures, (d) rotary cell cultures[169]

The liquid overlay method relies on the inhibition of cell adhesion to a pre-coated
surface. Hanging drop method allows the cells to aggregate spontaneously in the bottom of a
droplet of culture media. Spinning flask and rotary cell cultures keep the cells spinning to form
3D MCS by using continuous stirring. The ULA plates facilitate 3D MCS formation on a
hydrophilic, neutrally charged coating that is covalently bound to the polystyrene well
surface[167]. The advantages and disadvantages of these methods are summarized in Table 4.1.

Table 4.1. Comparison of scaffold-free techniques used for 3D MCS formation
Method
Liquid overlay

•
•

Advantages
Long culture period
Low cost

Disadvantages
• Variation in size
and shape
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•

Hanging drop

•
•
•

Spinning flask/Rotary cell

•
•
•

ULA plates

•
•
•

Easy to handle

Uniform size and
shape control
Low cost
High
reproducibility
Production of a big
number of MCS
Long culture period
Production of large
MCS
Long culture period
Uniform size and
shape
Scalable for high
throughput
screening

•
•
•
•
•
•
•
•
•
•

Hard to observe and
harvest
Low throughput
Intensive labor
Limited culture
period
Low throughput
Variation in size
and shape
Require specialized
equipment
Explosion to shear
stress
Various seeding
conditions
Costly

4.3 Introduction on the methods of imaging 3D MCS
Microscopy techniques that are commonly used to image monolayer cultured cells are
sometimes unsuitable for imaging 3D MCS due to their thick structures that prevent light from
penetrating deep without significant distortion[170]. Imaging techniques for thicker biological
specimens with high resolution have been more recently developed such as confocal laser
scanning microscopy (CLSM) and multiphoton microscopy[170].
Confocal laser scanning microscopy is a high-resolution imaging technique that is based
on point illumination with a laser on a sample and spatial filtering of the returning light by a
pinhole in an optically conjugated plane in front of the detector. CLSM can be used in both
fluorescence mode and reflectance mode. Because only light from the sample that are very
closed to the focal plane can be detected, the resolution is much better than wide-field
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microscopes. The three-dimensional structures of a sample can be reconstructed with twodimensional images captured at different depths. The penetration depth in thick samples is
limited because the light scattering in such samples causes the illuminating beam to
defocus[170]. The amount of light that passes through the pinhole will also decrease as the
sample depth gets deeper, effectively limiting the resolution. Penetration depth of the light also
depends on the nature of the sample, the NA of the objective and the wavelength of the
laser[170]. Generally, excitation laser of longer wavelength can penetrate deeper into samples
due to less absorption and scattering. It is reported that the penetration depth of CLSM on 3D
MCS is limited to roughly 100 µm[171, 172].
Multiphoton microscopy is based on the principle that two or more photons of lower
energy than the energy that is needed for one photon excitation can jointly excite a fluorophore
in one quantum event[173]. Such multi photons have to be absorbed simultaneously at the focal
point during the excitation, resulting in a high spatial resolution without the need for spatial
filtering. In addition, because multi photons used for excitation have longer wavelengths, the
penetration depth is improved up to about 1 mm[174].
4.4 Materials and Methods
4.4.1 Materials. Hela, Hep3b, MDA-MB-231, MDA-MB-468 and A549 cell lines were
purchased from ATCC (Manassas, VA, USA). Hela-eGFP cells were purchased from Cell
Biolabs, Inc. (San Diego, CA, USA). Dulbecco’s Modification of Eagle’s Medium (DMEM),
Minimum Essential Medium (MEM) were purchased from Corning (Corning, NY, USA). RPMI
1640 medium, Non-Essential Amino Acid (NEAA) and Trypsin-EDTA were purchased from
Thermo-Fisher. Ultra-low Attachment 96 well plates were purchased form Corning. Collagen;
3D viability assay kit and Snarf-1 were purchased from Fisher.
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4.4.2 3D MCS formation under different conditions. The formation and growth of 3D
MCS depend on many factors such as cell types, seeding densities, external forces and
extracellular matrix. In this study, we tried to grow 6 cancer cell lines in three-dimensional
configuration using Corning ultra-low attachment (ULA) 96 well plate and tested the effects of
three different conditions, namely seeding number, centrifugation, and collagen on the formation
of 3D MCS for each cell line.
4.4.2.1 3D MCS formation by different cell types. Some types of cells tend to selfassemble into spheroids in the Corning ultra-low attachment well plates while others tend to
form loose clusters of cells under the same condition. In order to investigate the formation of 3D
MCS by different cell types, Hela, Hela-eGFP, Hep3b, MDA-MB-231, MDA-MB-468 and A549
cells were seeded in the Corning ultra-low attachment 96 well plates at a seeding density of 1000
cells per well. The growth media was changed every other day by replacing 100 μL of the media
in the well with 100 μL fresh media to maintain a 200 μL total media volume. The morphology
of 3D MCS of each cell line was observed on an inverted microscope.
4.4.2.2 3D MCS formation with different seeding densities. The seeding density of cells
at the beginning of growth is a fundamental factor that affects the size of the spheroids.
Typically, a spheroid larger than 500 μm in diameter would develop a necrotic core, which better
reflects in vivo tumor growth. In order to investigate the influence of seeding density on the
formation and size of 3D MCS, Hela, Hela-eGFP, Hep3b, MDA-MB-231, MDA-MB-468 and
A549 cells were seeded in the Corning ultra-low attachment 96 well plates at a series of seeding
densities of 500, 1000, 2000, 5000 and 10000 cells per well. The cell growth media was
changed every other day by replacing 100 μL media in the well with 100 μL fresh media to
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maintain a 200 μL total media volume. The morphology of 3D MCS of each cell line was
observed on an inverted microscope.
4.4.2.3 3D MCS formation with and without centrifugation. External force, most often
centrifuge, is required to facilitate 3D MCS formation for some types of cells. The
recommended spin speed from the vendor is 200 g for 5 min at seeding. In order to investigate
the influence of external force on the formation of 3D MCS, Hela, Hela-eGFP, Hep3b, MDAMB-231, MDA-MB-468 and A549 cells were seeded in the Corning ultra-low attachment 96
well plates at a seeding density of 1000 cells per well with or without centrifuge. Cell growth
media was changed every other day by replacing 100 μL media in the well with 100 μL fresh
media to maintain a 200 μL total media volume. The morphology of 3D MCS of each cell line
was observed on an inverted microscope.
4.4.2.4 3D MCS formation with and without extracellular matrix (ECM). Extracellular
Matrix (ECM) is an important component of the tumor environment in vivo. It provides
structural support for cell-cell interactions. Some cell types of 3D MCS cultured in vitro need a
long time to develop ECM so adding a small portion of ECM (collagen or fibroblast) at seeding
can greatly improve the formation of 3D MCS by increasing the attachment among cells. In
order to investigate the influence of ECM on the formation and growth of 3D MCS, Hela, HelaeGFP, Hep3b, MDA-MB-231, MDA-MB-468 and A549 cells were seeded in the Corning ultralow attachment 96 well plates at a seeding density of 1000 cells per well with or without 1%
collagen. The cell growth media was changed every other day by replacing 100 μL media in the
well with 100 μL fresh media to maintain a 200 μL total media volume. The morphology of 3D
MCS of each cell line was observed on an inverted microscope.
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4.4.3 Viability assay for 3D MCS. The LIVE/DEAD Viability/Cytotoxicity kit from
ThermoFisher was used to assess the viability of the cells inside 3D MCS. Briefly, Hela cells or
A549 cells were seeded in the Corning ultra-low attachment 96 well plate to form 3D MCS using
the method described above. At day 8-10 when the 3D MCS were at ~ 500 μm in diameter, three
3D MCS were transferred to a glass bottom dish containing 200 µL of total growth media for
each cell line. An equal volume of the LIVE/DEAD kit reagents were added to the 3D MCS
which were incubated for 45 mins at room temperature. 3D MCS were then washed 3 times with
PBS and imaged using a Leica DMIRE2 confocal microscopy. Fluorescence at ex = 494 nm
and em = 517 nm was monitored for live cells, while Fluorescence at ex = 528 nm and em =
618 nm monitored for dead cells. Images were acquired using the MetaMorph software and
analyzed using the ImageJ software.
4.4.4 pH gradient inside 3D MCS. A fluorescent dye SNARF-1 was used to test the
pH gradient inside 3D MCS. SNARF-1 is typically used by exciting the dye at one wave length
between 488 nm and 530 nm while simultaneously monitoring the emission at two wave lengths,
typically about 580 nm and 640 nm. The pH can be determined by the ratio of these two
fluorescent signals. Hela cells or A549 cells were seeded in the Corning ultra-low attachment 96
well plate to form 3D MCS using the methods described above. At day 8-10 when the 3D MCS
were at ~ 500 μm in diameter, three 3D MCS were transferred to a glass bottom dish containing
200 µL of total growth media for each cell line. SNARF-1 was dissolved in anhydrous DMSO at
concentration of 100 M and added to 3D MCS in the glass bottom dish to a final concentration of
10 μM. The 3D MCS were then incubated for 45 mins at 37°C, washed 3 times with PBS and
imaged using a Leica DMIRE2 confocal microscopy.
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Figure 4.3. The emission of SNARF indicates pH is correlated to the ratio of fluorescence at
580/640 nm[175]

𝑅 − 𝑅𝐵 𝐹𝐵(𝜆2)
𝑥
]
𝑅𝐴 − 𝑅 𝐹𝐴(𝜆2)

pH = p𝐾𝑎 − log[

The pH at a given point in the fluorescent images can be estimated using the above
equation, where pKa of SNARF-1 is ~ 7.5, λ1= 580 nm, λ2= 640 nm, R is the ratio of the
fluorescence intensities at the two wave lengths (F λ1/F λ2). Subscripts A and B represent the
limiting values at the acidic and basic endpoints, respectively. From the equation we can see pH
is directly correlated to the R value. The higher R is, the lower pH would be. However, the
background signal needs to be subtracted before the calculation of R. Images were acquired
using the MetaMorph software and analyzed using the ImageJ software. One z-stack picture at
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100 m above the base of each 3D MCS was selected for the analyses and divided into seven
areas using concentric circles. Each of the seven areas was numbered 1 to 7 from the center to
the edge. The mean value of the 2 emission fluorescence signals of each region was measured.
The R value of each region was then calculated after subtracting the background noise.
4.5 Results and Discussion
4.5.1 3D MCS formation under different growth conditions. Different conditions of
culturing 3D MCS in Corning ultra-low attachment 96 well plate is described in the above
method sections. The impact of such different conditions on the formation of 3D MCS are
showed below.
Under the same culture conditions, different cell lines form 3D MCS of different
morphology. For example, after 5 days in culture, Hep3b cells formed tight spheroids of 300 µm
in diameter with smooth edges. Hela cells also formed spheroids of 500 µm in diameter with
rough edges. However, MDA-MB-468 cells formed very loose spheroids while Hela-eGFP cells
grew into only irregularly shaped aggregates (Figure 4.4, scale bar = 100 µm).
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Figure 4.4. Morphology of Hep3b cells (upper left), Hela cells (upper right), MDA-MB-468
cells (lower left) and Hela-eGFP cells (lower right) after 5 days in culture in the ULA 96 well
plates with same seeding conditions: 1000 cells/well seeding density, without collagen and
centrifuge.

The seeding density fundamental impacts the growth and morphology of 3D MCS. For
example, the morphology of MDA-MB-468 cells with seeding densities of 500, 1000, 2000,
5000 and 10000 cells per well in Corning ultra-low attachment 96 well plates is presented in
Figure 4.5 (scale bar = 500 µm), which shows that a higher seeding density of MDA-MB-468
cells not only yielded larger spheroids after the same days of culturing, but also shortened the
time needed for the 3D MCS to eventually turn from the tight round morphology to the more
edgy and spread-out morphology.
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Figure 4.5. 3D MCS of MDA-MB-468 cells after 5, 7, 9 and 11 days of culturing in ULA 96
well plates, starting with different seeding densities

Figure 4.6 compares the growth of Hela-eGFP cells with and without centrifugation.
With centrifugation at seeding, Hela-eGFP cells formed spheroids with thin branches of spread
cells; without centrifugation at seeding, Hela-eGFP cells yielded no spheroids but only loose
aggregates.

96

Figure 4.6. Hela-eGFP growth in ULA 96 well plates 5, 7- and 9-days after seeding with and
without centrifugation.

A comparison of the morphology of MDA-MB-468 spheroids with and without collagen
at seeding is showed in Figure 4.7. Without collagen at seeding, MDA-MB-468 cells formed
looser spheroids compared to the group with 1% collagen (scale bar = 500 µm).
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Figure 4.7. MDA-MB-468 3D MCS growth in ULA 96 well plates at day 5, 9, 13 and 17 after
seeding with and without collagen.

In order to construct a tight multi-cellular spheroid of different cell lines with a diameter
of 500 µm, the selection of seeding density, external centrifugation force and collagen must be
taken into consideration. As we mentioned before, spheroids with diameters larger than 500 µm
commonly have a necrotic core surrounded by a viable layer of quiescent zone and an outer shell
of proliferating cells[176, 177]. The gradients of metabolites, oxygen, nutrients and pH inside
the 3D MCS make them a more physiologically relevant platform for testing drug delivery
systems than 2D cell models. 3D MCS as large as 500 µm can be obtained either by growing
them for a long period of time or by increasing the seeding density.
The growth of 3D MCS are quite dependent on cell types as some cell lines tend to grow
tighter rather than bigger whereas other cell lines are likely to form loose or twin spheroids when
a high seeding density is applied. For example, Hep3b cells can form tight spheroids without
centrifugation or collagen. They tend to grow tighter and tighter after incubating for a long
period of time while the size of the spheroids increases very slowly (Figure 4.8).
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Figure 4.8. 3D MCS of Hep3b cells at seeding density of 2000 cells/well without centrifugation
or collagen

In contrast, 3D MCS of MDA-MB-468 cells started to show scattering structures on the
outer rim at day 11 after 5000 cells per well were seeded. The same scattering structure was
observed at day 9 when 10,000 cells per well were seeded (Figure 4.5).
In this study, a library of 3D MCS of six human cancer cell lines were constructed. Table
4.2 lists the optimized conditions to obtain tight 3D MCS of 500 µm in 7-10 days of culturing for
the six cell lines. These 3D MCS could serve as better models than monolayer cancer cell
cultures to test drug delivery systems.
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Table 4.2. Optimized Conditions to Construct 3D MCS of Six Different Human Cancer Cell
Lines
Cell Line

Type of Cancer

Hela

Human
Cervical
Human
Cervical
Human Liver
Human Breast
Human Breast
Human Lung

Hela-eGFP
Hep3b
MDA-MB-231
MDA-MB-468
A549

Seeding
Density on 96
well ULA plate
500

External Force
(Centrifuge)
N

Extracellular
Matrix
(Collagen)
N

500

Y

Y

4000
3000
2000
3500

N
Y
Y
Y

N
Y
Y
N

4.5.2 Imaging the viability of cells in 3D MCS. Figure 4.9 shows the image of a 100
m deep cross section near the core of 3D MCS of A549 (left) and Hela (right) cells. The green
signals from the fluorophore Calcein-AM represent the live cells while the red signals from the
fluorophore ethidium homodimer-1 represent the dead cells. The confocal images of both cell
lines show that the green signals are concentrated in the peripheral areas, indicating a
proliferation zone while the red signals distribute mainly in the core, indicating a necrotic zone.
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Figure 4.9. Confocal Image of the Viability of Cells in A549 (left) and Hela (right) 3D MCS.

4.5.3 pH gradient in 3D MCS. pH gradient inside 3D MCS of Hela cells is indicated by
R values.
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Figure 4.10. Confocal Images of Hela 3D MCS with SNARF-1 at two channels (580 green, 640
red)
Area
R

1
0.098

2
0.073

3
0.071

4
0.066

5
0.043

6
0.037

pH gradient inside 3D MCS of A549 cells is indicated by R values.

7
0.028
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Figure 4.11. Confocal Images of A549 3D MCS with SNARF-1 at two channels (580 green, 640
red)
Area
R

1
0.335

2
0.274

3
0.212

4
0.161

5
0.108

6
0.074

7
0.042

From the equation
𝑅 − 𝑅𝐵 𝐹𝐵(𝜆2)
𝑥
]
𝑅𝐴 − 𝑅 𝐹𝐴(𝜆2)

pH = p𝐾𝑎 − log[

where pKa of SNARF-1 is ~ 7.5. λ1= 580 nm, λ2= 640 nm, R is the ratio of the
fluorescent intensities at the two wave lengths (F λ1/F λ2). Subscripts A and B represent the
limiting values at the acidic and basic endpoints, respectively. For the same sample RA, RB,
FA(λ2) and FB(λ2) are constant, which means the pH is a function of a single variable R. The
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higher R is, the lower the pH. Figure 4.12 shows that, in both cell lines, the R value increases
from area 7 to area 1 of the concentric circles, indicating a decrease of pH from the peripheral
area to the core area of the 3D MCS of both cell lines.
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0
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8

r e a

Figure 4.12. R values of different areas in Hela and A549 3D MCS

The exact pH values were not calculable due to the lack of RA, RB, FA(λ2) and FB(λ2)
values. It is reported that the value of RA, RB from limiting acidic and basic conditions,
respectively, can be measured using nigericin calibration[178]. Nigericin is an antibiotic which
help equilibrate the pH inside and outside of cells. The idea of using nigericin is to achieve an
equilibration of pH inside 3D MCS after 45 min incubation in acidic or basic buffers, so that the
RA, RB, FA(λ2) and FB(λ2) values can be constant. After trying nigericin calibration with pH 7.4
and 6.0 buffer on both Hela and A549 cells, large variations on all RA, RB, FA(λ2) and FB(λ2) values
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were observed. This is probably because of the light penetration and defocusing issues from the
confocal microscopy.
Nevertheless, the R values of the areas defined by the concentric circles in each sample
demonstrate a clear increasing trend from the peripheral to the core of the spheroids,
demonstrating the acidification inside the 3D MCS under our studies.
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Anti-Cancer Activity of pH-Sensitive Fliposomes on 3D MCS

5.1 Introduction: Importance of Anti-cancer Activity Test on 3D MCS
Current studies and screening of anti-cancer drug activities mainly rely on twodimensional models of cultured cells in vitro and animal models in vivo. In vitro 2D monolayer
cell cultures lack the cell-cell and cell-matrix interactions. They also lack, the variations of
oxygen level, metabolite concentrations and acidic extracellular pH, which are usually observed
in solid tumors. Such deficiencies make the monolayer cells weak models to predict anticancer
activities of drugs and drug delivery systems. Many outcomes of studies using 2D are different
from those using 3D cell culture models[179-181]. For example, Colley et al. reported that it is
critical to deliver drugs deep into the core of the 3D MCS model of head and neck squamous cell
carcinoma cells to take effect while only a short contact of the drug with the corresponding 2D
monolayer cells is required to show substantial decrease of the cancer cell viability[182].
Sprague et al. reported that dendritic cells cultured in 3D MCS can mimic the
microenvironments of ovarian and breast cancer through their interaction with collagen proteins,
which is not available in 2D models[183].
The in vivo animal models are not always predictive of human responses to anticancer
drugs because of the following several reasons: 1) The widely used murine tumors do not behave
like human tumors; 2) The stromal components are not of human origin; 3) The growth rates of
xenograft tumors are often faster than primary human tumors[184-186]. The interspecies
differences can be profound on extrapolation and interpretation of experimental results[187].
Animal studies sometimes can be complex, unpredictable and can have ethical issues[159]. For
example, Zheng et al. found that after developing a novel human gastric tissue-derived

106
orthotopic and metastatic mouse model of human gastric cancer, it was difficult to achieve the
normal function of the implanted human gastric tissue in mouse[188]. There are some other
disadvantages of animal models such as cost of time/money and the low-throughput nature of
such experiments.
3D MCS have been used for broad studies in anti-cancer drug development as they
provide a good in vitro system to mimic the solid tumors more closely than 2D culture
systems[189, 190]. Moreover, they can be used to represent the physiological conditions for
some rare cells. For example, cancer stem cells are considered to be responsible for the relapse
of cancers after treatment[191]. When cultured as spheroids in 3D these cells maintain key
properties including gene expression level, tumorigenic activity, differentiation potential and
resistance to chemotherapies[192-194]. For example, Fang et al. reported that primary human
colon tumor cells in 3D MCS maintained CD133 expression and exhibited resistance to
chemotherapy-induced apoptosis, which was not observed in their 2D cultures[193]. Similarly,
cells within 3D MCS of ovarian cancer showed increased proliferation and migration potential
compared to those that were cultured in 2D[195]. These examples illustrate that 3D MCS can
serve as a better platform for cancer research by providing a more physiologically relevant
microsystem[179, 196].
5.2 Materials and Methods
5.2.1 Materials. MDA-MB-231, Hela and A549 cells were purchased from ATCC.
CellTiter 96 AQueous OneSolution cell proliferation assay kit and CellTiter-Glo 3D cell viability
assay kit were purchased from Promega. Dulbecco’s Modification of Eagle’s Medium (DMEM)
and Minimum Essential Medium (MEM) were purchased from Corning. Ultra-low Attachment
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96 well plates were purchased form Corning. Trypsin-EDTA and Collagen were purchased from
Thermo-Fisher.
5.2.2 Cytotoxicity assays for DOX-loaded liposomes on 2D monolayer cells and on
3D MCS. CellTiter 96 AQueous OneSolution cell proliferation assay (Promega Corp., WI, USA)
was used to test the cytotoxicity of DOX-loaded liposomes on monolayer cancer cells. MB231
cells (~ 10,000 cells/well) were seeded on 96 well plates and grown overnight. At about 80%
confluence, the cells were treated with free DOX and liposomal DOX at a dosages of 0.05, 0.1,
1, 2, 5, 10, 50, 100, 200 µg DOX per mL in complete medium. The cells were incubated at 37 °
C with 5% CO2 for 72 h before viability measurements. After incubation the cells were washed
with 100 µL PBS three times and then supplemented with 100 µL/well of growth media and 20
µL/well of the CellTiter Assasy Reagent. The cells were further incubated at 37 °C with 5%
CO2 for 2 h. The absorbance at 490 nm was measured by a 96 well-plate reader. The cells
treated with growth media without free or liposomal doxorubicin were assayed in the same way
and taken as the control for 100% viability. Each test was performed in triplicate.
CellTiter-Glo 3D cell viability assay (Promega Corp., WI, USA) was used to test the
cytotoxicity of DOX-loaded liposomes on 3D MCS. MB231 cells (~ 3000 cells/well), A549
cells (~ 3500 cells/well) and Hela cells (~ 500 cells/well) were seeded on Corning ULA 96 well
plate to form 3D MCS using the method described above. After 8-10 days when the spheroids
grew to ~500 µm in diameter, they were treated with free Dox and liposomal Dox at dosages of
0.05, 0.1, 0.5, 1, 10, 50, 100, 400 and 800 µg DOX per mL in complete medium. The 3D MCS
were incubated for 8 h and 72 h at 37°C with 5% CO2. The CellTiter-Glo 3D Reagent was
thawed at 4°C overnight before the experiment. On the day of experiment the reagent was
equilibrated to RT by placing it in a 22°C water bath for approximately 30 minutes and gently
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mixed well by inverting the contents. The 3D MCS of each treatment group were transferred to
an opaque-walled 96 well plate with 100 µl medium in each well. An equal volume of 3D
reagent was added to each well of the plate. The plated was shaken for 5 minutes and incubated
for additional 25 minutes at RT to stabilize the luminescent signal. The luminescence was
measured by a 96 well plate luminescence reader. The cells treated with growth media without
free or liposomal doxorubicin were assayed in the same way and taken as the control for 100%
viability. Each test was performed in triplicate.
5.2.3 Confocal microscopic imaging of 3D MCS after treatment with DOX-loaded
liposomes. MB231 cells (~ 3000 cells/well), A549 cells (~ 3500 cells/well) and Hela cells (~
500 cells/well) were seeded on Corning ULA 96 well plate to form 3D MCS using the method
described in Section 4.5.1. After 8-10 days when the spheroids were as large as ~500 µm in
diameter, they were treated with free Dox and liposomal Dox at 10 µg Dox per mL in complete
medium. The spheroids were incubated at 37°C with 5% CO2 for 4 h and then washed three
times with PBS. The spheroids were transferred to a glass bottom dish for imaging on a Leica
DMIRE2 laser confocal microscope with the following setup: Exposure (1s), Gain (1x), Image
Scaling (1000-3000) and z step (10 µm). The excitation and emission were at 470 nm and 585
nm, respectively. Images were acquired using the MetaMorph software and analyzed using the
ImageJ software.
5.3 Results and Discussion
5.3.1 Cytotoxicity of liposome formulations on 3D MCS of different cell lines.
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Figure 5.1. Viability of MB231 monolayer cells (left) and MB231 3D MCS (right) after 72 h
drug exposure

Table 5.1. IC50 of Different Dox Formulations on monolayer and 3D MCS of MDA-MB-231
cells after 72 h exposure.
IC50 (µM)

Free DOX

2D
3D

1.11
11.86

DOX-loaded Non
pH-sensitive
Control (NC)
Liposome
1.68
37.72

DOX-loaded
Fliposome

1.35
22.54

Fifty percent inhibitory concentration (IC50) values of each Dox formulation was
calculated from data shown in Figure 5.1 using the GraphPad Prism software. Against 2D
monolayer of MDA-MB-231 cells free DOX showed the lowest IC50 (1.11 µM); DOX-loaded
Non pH-sensitive control liposome group gave the highest IC50 (1.68 µM); IC50 of DOX-loaded
Fliposome was in the middle (1.35 µM). No statistically significant difference was found
between these groups. Against 3D MCS of MDA-MB-231 cells same trend of IC50 values was
observed: free DOX gave lowest (11.86 µM), DOX-loaded Non pH-sensitive control liposome
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gave highest (37.72 µM), DOX-loaded Fliposome was in the middle (22.54 µM). However,
each of the three groups was significantly different (p < 0.01) from the other two groups.

Figure 5.2. Cell Viability of A549 3D MCS at 8 h exposure (left) and 72 h exposure (right)

Table 5.2. IC50 of Different Dox Formulations on A549 3D MCS after 8 h and 72 h exposure
IC50 (µM)

Free DOX

8h
72 h

120
21.99

DOX-loaded Non
pH-sensitive
Control (NC)
Liposome
159.1
18.88

DOX-loaded
Fliposome

68.6
~5.02

The IC50 values (Table 5.22) calculated from the raw data of Figure 5.2 indicated that
after 8 h incubation with 3D MCS of A549 cells DOX-loaded Non pH-sensitive liposomes gave
the highest IC50 (159.1 µM) among the three Dox formulations. The DOX-loaded Fliposome
group showed the lowest IC50 (68.6 µM) and the IC50 of the Free DOX group was in the middle
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(120 µM). After 72 h incubation the free DOX group showed the highest IC50 (21.99 µM),
followed by the DOX-loaded Non pH-sensitive liposome group (18.88 µM) while the DOXloaded Fliposome group presented the lowest IC50 (~5.02 µM).

Figure 5.3. Cell Viability of Hela 3D MCS after exposure to Dox formulations for 8 h (left) and
72 h (right)

Table 5.3. IC50 of Different Dox Formulations on Hela 3D MCS after 8 h and 72 h exposure
IC50 (µM)

Free DOX

8h
72 h

59.57
0.74

DOX-loaded Non
pH-sensitive
Control (NC)
Liposome
191.9
1.62

DOX-loaded
Fliposome

282.3
1.09

From the raw data presented in Figure 5.3 we can calculate IC50 values of each
formulation on Hela 3D MCS after 8 h and 72 h incubation (Table 5.3). After 8 h exposure the
DOX-loaded Fliposome group presented the highest IC50 (282.3 µM); the Free DOX group gave
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the lowest IC50 (59.57 µM); IC50 of DOX-loaded Non pH-sensitive liposome group was in the
middle (191.9 µM) of the three. After 72 h incubation the DOX-loaded Non pH-sensitive
liposome group showed the highest IC50 (1.62 µM), followed by the DOX-loaded Fliposome
group (1.09 µM) while the Free DOX group gave the lowest IC50 (0.74 µM).
After 72 h drug exposure free DOX imposed more cytotoxicity then both liposomal DOX
formulations in both monolayer and 3D MCS cell culture models. This could result from the
extended killing effect of free DOX, which is more exposed to the cancer cells while part of the
DOX of the liposomal formulations were still concealed inside the liposomes. Nonetheless, the
DOX-loaded Fliposome gave a significantly smaller IC50 value than the DOX-loaded non pHsensitive control liposome (p < 0.01) against 3D MCS. This is consistent with the proposed pHtriggered release of DOX from the DOX-loaded Fliposome in response to the low pH
environment inside the 3D MCS, where more DOX would be released from the fliposomes than
the non pH-sensitive control liposomes. The IC50 values of all 3D MCS groups were much
higher than those of 2D monolayer cells under the same drug treatment, indicating a generally
greater drug resistance of 3D MCS.
The cytotoxicities of different treatment groups on Hela and A549 3D MCS over 8 h and
72 h showed some different patterns (Figure 5.2 and Figure 5.3). After 8 h drug exposure, Free
DOX showed higher cytotoxicity than liposomal-DOX groups against Hela 3D MCS, but lower
cytotoxicity against A549 3D MCS. After 72h incubation an apparent increase in cytotoxicity
can be observed on both cell lines from DOX-loaded Fliposome groups comparing with Non pHsensitive liposome control group, which is parallel with the results from MDA-MBA-231 cells.
These results suggest that, after long time exposure, the enhanced cytotoxicity in 3D MCS but
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not in monolayer cancer cells could be attributed to the enhanced release of DOX from the
fliposomes in the acidic environment inside 3D MCS.
5.3.2 Distribution of DOX-loaded liposomes in 3D MCS.

Figure 5.4. Confocal Images of MDA-MB-231 3D MCS (100 µm deep) Treated with Free Dox
(left), Dox-loaded Non pH-sensitive liposome (middle) and Dox-loaded Fliposome (right) for 4 h

After 4 h incubation with Free DOX, Dox-loaded Non pH-sensitive control liposome or
DOX-loaded fliposomes groups, confocal microscopy images at about 100 µm deep in MDAMB-231 3D MCS show much stronger fluorescent signals of 3D MCS treated with liposomal
DOX than those with Free DOX. An intense ring of DOX accumulated in the outer proliferative
cells of each 3D MCS was observed, indicating limited penetration of all formulations after 4 h
incubation.
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Figure 5.5. Confocal Image of A549 3D MCS (100 µm deep) Treated with Free Dox (left), Doxloaded Non pH-sensitive liposome (middle) and Dox-loaded Fliposome (right) for 4 h

Figure 5.5 shows that DOX-loaded liposomal groups (middle and left) gave much greater
fluorescence than the free DOX group in A549 3D MCS, indicating more accumulation of DOX
inside 3D MCS at 100 µm depth after 4 h incubation. The fluorescent signal of A549 3D MCS
was more evenly distributed in the 100 µm detection section compared to 3D MCS of MDAMB-231 cells.
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Figure 5.6. Confocal Image of Hela 3D MCS (100 µm deep) Treated with Free Dox (left), Doxloaded Non pH-sensitive liposome (middle) and Dox-loaded Fliposome (right) for 4 h.

No significant difference of fluorescent intensity was observed within groups of Hela 3D
MCS after treatment by free or liposomal DOX for 4 h. This result suggests that both free DOX
and DOX-loaded liposomes could penetrate into Hela 3D MCS with similar efficiency given 4 h
of exposure time.
This study compares the penetration of free DOX, DOX-loaded Non pH-sensitive
liposome and DOX-loaded Fliposome into 3D MCS of 3 cancer cell lines in 4 h of exposure
time. Liposomal DOX groups showed more penetration than free DOX in 3D MCS of MDAMB-231 and A549 cell lines, while no significant difference of penetration in Hela 3D MCS was
observed between liposomal DOX and free DOX. This result indicates a cell line dependence of
DOX penetration into 3D MCS, which is consistent with the report by Namhuk, et al. [197].
Several studies have reported that cellular accumulation of the weakly-basic drug Doxorubicin
(DOX) has been shown to decrease at low extracellular pH[198-200]. At low pH, the ionized
DOX has low lipid solubility and high electrical resistance, leading to a greatly reduced
membrane penetration. The insufficient penetration of free DOX into A549 spheroids can be a
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reason for the higher cell viability of the free DOX treatment group compared to liposomal DOX
groups after 8 h drug exposure (Figure 5.2). There was no significant difference of penetration
between DOX-loaded Non pH-sensitive liposome and DOX-loaded Fliposome in 3D MCS of all
3 cell lines after 4 h incubation, suggesting that the enhanced cytotoxicity of the DOX-loaded
fliposomes observed in 3D MCS of all 3 cell lines (Figure 5.1, 5.2 and 5.3) resulted from the
triggered release of DOX from fliposome in response to the reduced pH inside the 3D MCS.
The confocal scanning of 3D MCS was performed with z-stack sectioning of 10 µm per
step from the bottom to top. The 100 µm depth was chosen due to the limit of the confocal laser
scanning technique[170]. Light penetration depth above 100 µm is greatly affected by the
scattering in the sample and the defocusing of the illumination beam[171, 172]. The 100 µm
depth was counted from the starting point where the fluorescent signal start to increase from the
background (Figure 5.7). To improve the light penetration depth and thus to obatin images of
higher resolution from thick 3D MCS, multiphoton microscopy can be used in the future
studies[201]. Cryosection is another alternative way to address the light penetration issue by
cutting the spheroids into sections of 10 – 20 µm in thickness. High resolution images of each
section can then be easily obtained using confocal microscope. The disadvantage of this method
is that the samples need to be fixed and sacrificed during the measurement[202].

Fluorescence intensity (RLU)
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Figure 5.7. DOX Fluorescence in Different Depth of A549 3D MCS after 4 h Incubation

The exact mechanism of the penetration of DOX-loaded non pH-sensitive liposomes and
pH-sensitive fliposome into 3D MCS is unclear. But the size and charge of the liposome
formulations play an important role in the drug accumulation inside 3D MCS. Kostas et al,
investigated the impact of the size and surface charge of liposomes on the penetration into
LNCap-LN3 prostate cancer 3D MCS[203]. It was discovered that small liposomes (diameter <
150 nm) can penetrate up to approximately 80 µm deep after 2 h exposure time while larger
liposomes (diameter > 800 nm) had minimal interaction with the MCS cells and very limited
penetration. Also, cationic liposomes showed minimal intratumoral penetration into the 3D
MCS due to the strong electrostatic binding of liposomes to the cancer cells at the peripheral
region of the 3D MCS[203]. The neutral charged fliposomes with small size (100 – 200 nm)
have been proved to be a promising pH-triggered drug delivery system.
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